<SEC-DOCUMENT>0001628280-15-000757.txt : 20150213
<SEC-HEADER>0001628280-15-000757.hdr.sgml : 20150213
<ACCEPTANCE-DATETIME>20150213171449
ACCESSION NUMBER:		0001628280-15-000757
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150213
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20150213
DATE AS OF CHANGE:		20150213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		15616245

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>boxaban8kdocument.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Boxaban 8K document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s75e865db8ebb42b8acaf70fa8d8bc5b3"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="51%"></td><td width="5%"></td><td width="44%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 13, 2015 (February 11, 2015)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="0%"></td><td width="33%"></td><td width="18%"></td><td width="5%"></td><td width="11%"></td><td width="33%"></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s75e865db8ebb42b8acaf70fa8d8bc5b3"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 11, 2015, Cumberland Pharmaceuticals Inc. issued a press release announcing an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:10pt;">) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Cumberland has completed manufacturing and received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) amendment and Phase II study associated with the product. A copy of the press release is attached as Exhibit 99.1.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s75e865db8ebb42b8acaf70fa8d8bc5b3"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="68%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">February 13, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated February 11, 2015</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseforboxaban-01.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Press release for Boxaban - 01</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sf8fde1a82efa486d92352bdad42f2fe2"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;"><img src="cumberlandpicture.jpg" style="height:140px;width:618px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cumberland Pharmaceuticals Announces Pipeline Expansion With Boxaban</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#8482;</sup></font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;(</font><font style="font-family:inherit;font-size:16pt;font-style:italic;font-weight:bold;">ifetroban</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">) Oral Capsule</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">- - FDA clears investigational new drug submission</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">- - Manufacturing completed and Phase II clinical development program underway</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NASHVILLE, Tenn., Feb. 11, 2015 /PRNewswire/ -- </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX)</font><font style="font-family:inherit;font-size:11pt;">&#32;today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:11pt;">) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Cumberland has completed manufacturing and received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) submission and Phase II study associated with the product.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"Physicians and patients alike are eager for viable new treatment options for AERD to help relieve symptoms and restore quality of life. This ifetroban clinical program is a truly exciting development, supported by laboratory findings in animal models of the disease," said Andrew White, M.D., lead investigator for the trial and researcher from Scripps Clinic in San Diego, CA. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Aspirin-exacerbated respiratory disease (AERD), also known as Samter&#8217;s Triad, is a respiratory disease involving chronic asthma and nasal polyposis that is worsened by aspirin or nonsteroidal anti-inflammatory drugs. Approximately one in 20 asthmatic adults (nearly 1 million patients in the United States) suffer from AERD and the disease awareness is growing within the medical community. AERD is characterized by sharp increases in inflammatory mediators and platelet activity within the respiratory system. Ifetroban, an active thromboxane receptor antagonist, may interfere with these pathways to modify the disease and provide symptom relief. Current treatment of AERD remains a challenge, as novel and effective treatment modalities are lacking for this unmet medical need. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"Patients with AERD often have the most severe and difficult to treat form of asthma. The manufacture of the oral capsule formulation and initiation of the AERD clinical development program by Cumberland represents a significant milestone for our collaboration," said John Oates, M.D., the Professor of Medicine and Pharmacology at Vanderbilt University. "Data from this important trial will help us to understand the potential for ifetroban in treating AERD while generating safety information that will allow us to consider ifetroban therapy for other patient populations."</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In 2011, Cumberland announced the acquisition of the ifetroban program in collaboration with Vanderbilt University and Cumberland Emerging Technologies (CET). Cumberland is also currently studying ifetroban in an injectable formulation in a Phase II study in patients with Hepatorenal Syndrome (HRS), a life-threatening condition involving progressive kidney failure. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">About Ifetroban </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ifetroban is a pharmacological antagonist of the thromboxane A2 / prostaglandin endoperoxide receptor (TPR). Ifetroban exhibits high-affinity for TPRs on platelets, vascular and airway smooth muscle and certain other cell types and lacks agonistic activity. Ifetroban also displays anti-platelet, antivasospastic and antibronchospastic activities and is effective in certain preclinical models of vasospasm, thrombosis, reperfusion injury and endothelial dysfunction, including models that are insensitive to aspirin. </font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sf8fde1a82efa486d92352bdad42f2fe2"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">About Cumberland Pharmaceuticals</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:11pt;">) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:11pt;">) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:11pt;">) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:11pt;">) Injection, for the treatment of hyponatremia and Omeclamox-Pak</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;for the treatment of </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:11pt;">&#32;and related duodenal ulcer disease. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland Pharmaceuticals Inc., please visit www.cumberlandpharma.com. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">About Cumberland Emerging Technologies</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Cumberland Emerging Technologies Inc. ("CET") is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc., and the state of Tennessee's Launch TN (formerly the Tennessee Technology Development Corporation). The mission of CET is to advance biomedical technologies and products conceived at academic research centers towards the commercial marketplace. CET manages the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing, and market issues that are critical to successful new biomedical products. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CET has sponsored Middle Tennessee's first life sciences incubator located in downtown Nashville adjacent to the Union Station Hotel and the Frist Visual Arts Center. This Life Sciences Center provides laboratory space, equipment and other support to a growing number of tenants who specialize in medical products and research advancements. For more information, visit www.CET-Fund.com. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">Forward-Looking Statements </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. </font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SOURCE: Cumberland Pharmaceuticals Inc. </font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investor Contact: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Media Contact: </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">John Lane &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Rebecca Kirkham </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Corporate Relations &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lovell Communications </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(615) 255-0068&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(615) 297-7766 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlandpicture.jpg
<TEXT>
begin 644 cumberlandpicture.jpg
M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`#3`Z`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]]****`"B
MBB@`HHHH`****`"BBB@`HHI&<*"3VH`6BOG'Q#^TP-7_`."GGAOX5:=J4_E:
M5X#O_$&KVL4Q$9DFO+6&W\Q0<%E6.8C/($G'WN?HZM:M%TU'FZJY$*D9WY>@
M4445D6%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44$X'-->3:A
M.1P,B@!U%>5?$#]LOX?_``WN9[6[\06VHZA;$K)8Z3$^H7,9]&2$,4_X%C\*
M\*^*7_!6^/PY%(OA[P#J%XPR%FU:_CLD^NR/S6_`[3770P->LTH1_3\R934=
M6?8[7"+U8#!QR:\`_;M_X*)_#[]A3X>7FH^)-5@NM=>%CIN@VLJM?7\FT[1L
MY*1YZR,`H]SQ7YZ_M'_\%:?C1XVM+BUT[5M*\'6DFY=NB6>+@J>S33-(V?=`
MAK\ZOC=K-[XGU6]U'4[V\U+4+QB\]U=S-//,WJSL2S'ZFOH\MX4E4FI8F5H]
MEU/.QF.]G%N!]M_\$'?V@_$'[5?_``6&^(_CWQ3.)M7\1>&+R>15SY5NGVFT
M5(4'9$0*H]A[U^XU?@#_`,&PXQ_P47\2_P#8G77_`*56M?O]7/Q;3C#'\D59
M*,4C#(9.6&O+75_F%%%%?,GM!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!110
M3@?2@`J#4M1BTJS>XGDCBAB!9WD<*J*!DDD\``5Y]^T3^TSX7_9S\)+J>OW3
M_:)RR6&GV^'N]1E`SLB3(SC/+$A5!R2!7QEXX^./B7]IS5A)XG>.VT$2;K;P
M];RL]FG(PT[$#[2_?Y@$4]%R-Q[,+@IUES[1[_Y$2J):'T_XH_;+A\52R6'P
M]TQ/$;ABC:O<RFWTJ(@\E&`+W&/2,;#T\Q:Y?Q-X%U'QMI#7'B_Q%J/B$R#<
MUC'_`*%I:^PMT.7'M,\E<]\.3^[C`X```'85Z3K/_(`_X#_2JJ)4Y)4_^#_7
MH"5]6?/OQ!TFUT&Q%I96\%I:PC;'%"@1$`[`#@"OFGXJ]9/K7T_\5_O2?C7S
M!\5>LGUKZ/+=;7,*VB/FOXH?ZQZ^>/BE_JY?Q_E7T/\`%#_6/7SQ\4O]7+^/
M\J^SP?0\3&_`SZK_`.#8C_E(OXD_[$ZZ_P#2JUK]_J_`'_@V(_Y2+^)/^Q.N
MO_2JUK]_J^$XQ_Y&+_PHZ>'_`/=?F_S"BBBOECW`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@!&8(N2<`5X_\`MC_M?:#^R1\-FU?4"+[5[_=;Z1I2/MEU&<#.
M,_PQJ,%W/"CU)4'T#XJ_$K1OA#\.M:\3:_>Q6&D:%:O>7<SG[J*,X`ZECP`H
MY)(`Y-?B#\=_VG-9_:X^-]_XPUAI(893]GTNP+Y33+-6^2(=MQ^\[?Q,3V"@
M>SE&5O%3<Y?!'?S\CFKUN33J>C:E\4=?^-_Q"NO%/BB_.HZS??)N"E(;6($E
M8(4R=D8].K')8DG->M_#O[D7U%>"_#P;O+QSTKVSP1XFL=/O(;1YUEOGP4LX
M$:>ZE_W(8P9&_!37TN,IQ@DDK6_`RIZ[GT;\.?N1_05Z3K/_`"`/^`_TKS/X
M:^'/&NJ0(^F^`O$3Q\8FU+RM,B/_``&9A,/^_1KTE?A!\2O$EH(KBY\'>'HN
M,JL5SJLF/KFW4'\Z^1KI<]^9?>=46TCP?XL.`S\^M?,/Q6X,F?7-?H)=?L%C
MQ#('UGQSXGG9N7CL;.SMH3]`\,CC_OL_6GP?\$P?A1<X.IV7B+5Y!U:XURYB
M#_5871?TKT\+F5"C;F;?HO\`.QG*$IZ(_&7XH#]Y)[5\[_%-L)+P>_:OZ,+7
M_@F'\"+:0,WP[TN[8=[NYN;K_P!&2-5I?^":?P"`.[X1^!9<]?-TJ*3_`-"!
MKV*7%F&I[0;^XX:^7SG&US\</^#8MQ'_`,%%_$N3C_BCKKCO_P`?5K7[_;AC
M-?GI_P`%)_V:?`'[,.@^$M3^'7A#0/`^HZA<W,%S<Z)9I8S3QB-#L9XP"5S@
MX)QQ7RA%\:/&.BR!K3Q9XEMBG(\O5)UQ^35\WG>9QQV)]O"-E9+7R-LMP<L-
M1]G+75_B?MV2!U-&><5^,FC?MT?%WP<X-CX^U\XYVW,JW2_B)0V?QKT;P)_P
M66^*GA"2--8M?#GB6$<.9K4VTS#V:(A1^*'Z5Y!Z!^JM%?$_PI_X+<^`_$K1
M6_BS1-8\+SM@//$/MMLOOE0'Q_P`U]4_"?X]>#?CCI1O/"?B71]>B49=;6X5
MI8O]^/[Z'V8"@#KZ*`<T4`%%%%`!1110`444-P#GI0`45\T?\%#/^"J/PM_X
M)O>'=/G\;:C=7FM:PK/IVAZ9&L]]=JIP9""RJD8/&]V`)!`R0<?"-W_P=U^$
M([IQ!\&?$LL&?D:37((W(]P(F`_,UZF$R3'8FG[6C3;7?1?F>?7S3"T)>SJU
M$GV/V%HK\=Q_P=W^%/\`HBOB#_PH(?\`XS1_Q%W^%/\`HBGB#_PH(?\`XS77
M_JOFG_/I_>O\SG_M[`?\_5^/^1^Q%&>:_'?_`(B[O"G_`$13Q#_X4$/_`,9K
ML/@S_P`'7GPE\;^*;:P\7>!_%G@JTN)%0WZRQ:E!!DXW.$VN`/55:HGPUF<8
M\SI/[T_U*AGF!DTO:K\3]6**R?!'C;2?B-X3TW7=#U"TU72-8M8[RRO+6420
MW4,BADD1AP5((((]:UJ\-IIM,]5.ZT#/-&:^9/\`@J-_P4@L?^"9?P6TGQIJ
M/A>]\66VJZNFE"UMKM;9D+122;]S*PQ^[QC'>OGS_@GK_P`'#&A_\%!/VI=%
M^&.G?#35_#5SJ]M=7"WUQJT=RD8@A:4@H(E)R%(Z\5Z%+*L54P[Q4(>XMWIT
MW..IF&'IUE0E/WGT]=C]'J***\\[0HSBBN(_:-^,2?L^_`WQCXXELI=2@\(:
M)=ZS):QN$>X6")Y"@8@@$[<9(-.,7)J,5JQ-V5V=OFBOQYM?^#N3PMJ%[#`G
MP7\0)YKA,G7X3C)`_P">-?L)$Q:-21@D#(]*[,;EN*P=OK,>6^QR87'T,3?V
M$KVW'445\O?\%3?^"EUC_P`$Q/A)H/B[4?"EYXLM];U8:6+>VO%M6B8Q22;B
MS*P(^3&,=ZPP^'J5ZBI4E=O9&]:K"E!U*CLD?4-%?GE_P3J_X.%O`G[?GQW_
M`.%?S>%K[P#K%[;--I+7VHQW,>J2*<O`K!%VN$^8`YW8('(P?T,5PW0@_C6F
M,P=;"U/98B/*R,+BJ6(A[2E*Z%HHHKE.@***\C_;<_;$\+_L-?LZZ[\1?%$P
M:QT>,+!:1N!-J-RW$5O'G^)C^0!/05=.G*I-4X*[>Q,YQA%SD[)'KF:*_(7P
MC_P=D^%_%WBS2M(C^#6OV\FIWD-H)3KT3",R.$W$>3R!G.,U^N]N[20J6&&(
MYKKQN6XK!M+$PY;['+@\=0Q,7*C+FL/HS01D5\I?\%5?^"H>G_\`!+KX>^%O
M$.H^$KWQ=%XHU&33DAM[U;4P,D1DW%F1L@@8Q7/A\/4KU%2I*\GL;UZT*,'4
MJ.R6Y]6T5^.X_P"#NWPJ3C_A2GB'_P`*"'_XS1_Q%W^%/^B*>(/_``H(?_C-
M>S_JQFG_`#Z?WK_,\S^WL!_S]7X_Y'[$45^._P#Q%W^%/^B*>(/_``H(?_C-
M'_$7?X4'_-%/$'_A00__`!FC_5C,_P#GT_O7^8?V[@?^?J_'_(_8BC/.*_'_
M`$G_`(.Z/!-QJ4*7WP<\46MH6Q)+!K,$[H/4*8U!^FX5^B7[#7[??P[_`."@
M?PN/BKX?ZL;N&V<0ZA87,?DWNES$9$<T>3C(SA@2K8.":XL9DV-PL?:8BFU'
MONOO1TX7,\+B)<E*HF^Q[=10#D9'(--E)6)B.H'%>:M3O'9HK\DOBA_P=:>&
M/A?\2_$?AJ?X/:[>R^'M4N=,>=-=B03&&5HRP7R3C.W.,]ZQ!_P=W>%#_P`T
M4\0?^%!#_P#&:]V/#.9R2E&E=/S7^9Y#SW`IM.HE;O<_8BBOQW_XB[_"@./^
M%*>(/_"@A_\`C-'_`!%W^%/^B*>(/_"@A_\`C-5_JQFG_/I_>O\`,7]O8#_G
MZOQ_R/V(HK\=S_P=W^%!_P`T4\0?^%!#_P#&:[K]F+_@YZ\._M.?M$^"OA[9
M_";6](N/&6KV^DQWDNM13);-,X0.4$0)`STS45.&\RA%SE2LEYK_`#*AG>"E
M)1C55WZGZG4$X%(IR!GK7'?M%?%N/X`_`#QOX[ELI-1A\%Z#>Z[):(X1KE;6
M!YC&&((4L$(R0<9KQ8Q<FHQW9ZDI**;?0[*BOQT7_@[L\*+_`,T5\0?AX@A_
M^,T__B+N\*?]$4\0?^%!#_\`&:]S_5C-/^?7XK_,\IY[@/\`GZOQ/V(HK\=_
M^(N_PI_T13Q!_P"%!#_\9H_XB[_"F?\`DBGB#_PH(?\`XS3_`-6,T_Y]/[U_
MF+^WL#_S]7X_Y'[$9YHK\>K/_@[L\'2WT2W/P:\30VY8"1XM;@D=%[D`QJ&/
ML2/K7Z`_L#_\%*/AO_P48^'MWKG@#4+D7&DR)%JFE7\0AOM-=P2N]`Q!5L-M
M=25.UAG((KDQF2X["Q]I7IM1[[K\#IPV9X6O+DI339]"4=**CN79$&WJ3BO+
M.\DS17Y1_'[_`(.E?#?P'^-_C#P//\(M=U"Y\(ZS=Z/)=IKD4:W#03-$7"F(
MX!VYQDU]_?L'_M7V_P"W#^REX3^*5IHT_A^V\5I<21V$TXG>W$5S+;G+@*#D
MQ$\#O7?BLKQ>'I1KUX6C+;Y['%0S'#UJCHTY7DMSUZBBBN`[0HHHH`****`"
MBBH-1OH].L9;B61(H85WR.[`*BCJ23P`!WH`GSBBOR0^)7_!V1X%\&>/];TC
M2/A=K?B33M,O9K6UU2/68[=-01&*B54,1*JV,C)Z$5]V_P#!-_\`X*#^&?\`
M@HY^SQ%X[T&W;2)XKR6PU#29[A99].F0@@,0!D,A5U.!D-Z@UZ6+R?&X>FJU
M:FU%G!ALRPU>;ITYIM=#Z"HHHKS3O"@G%%)(2J$@$D#C%#V`6BOS6_;R_P"#
MB_0OV%/VIO$GPQU#X8:QXBN?#PMRU_!J\=NDPE@2480QL1C?CKVKZA_X)V?\
M%)/`/_!1OX0KXE\*7:V6J6F(]7T*YE4WFDR^C`?>0_PR`88>AR!Z%;*L72HK
M$U(6@]GZG#1S'#U:KH0G>2Z'T110"&&0<BBO/.X***\^_:K^/$?[,/[.OC'X
M@S:=)J\'A#2I]4DLXY1$]PL2[BH8@A2?4BJA"4Y*$5=O0F4E&+E+9'H.:*_*
M?]GC_@Z.\-_M!?'?P9X$MOA'KFFW/C#6K31H[N37(I$MVGF6(.5$0)`W9QGM
M7ZJP,7A4GKWKKQN7XC"24<1'E;U6WZ'-A,;1Q,7.A+F2'T$XHKF_B_X_'PK^
M&'B'Q*UNUW'X>TRYU-X%;:TRP1-(5![$A<9]ZXTFVDCJ;25V=)17XZI_P=V^
M%`@)^"GB#T/_`!4$/_QFG?\`$7=X4_Z(IX@_\*"'_P",U[O^K&:=:7XK_,\E
MY[@;_P`5?B?L117X[_\`$7?X4(_Y(KX@_P#"@A_^,T0_\'=GA)YP)/@QXD2/
MN5UZ!C^1A'\Z/]6,T_Y]/[U_F"SW`?\`/U?C_D?L117YG?"+_@Z:_9\\>ZA#
M;>(M,\;^"3*0IN+W3X[NWC/N;=W?'OL_"OO;X"_M*>!OVG?!4/B/P%XKT3Q7
MHLWRFYT^Y641/_<=?O1N.ZN`1Z5YV*RW%X7_`'BFXKO;3[]CMP^.P^(_@S3?
M:^IW=%(&##(((J&_U"'3K:26:6.&.)"[.[!54`9))/0<5Q'5>Q.3BC-?(6H?
M\%A/!GB/Q%?V/PW\$_%/XRVVE3-!>:IX,\-R7FEQ2*3E%NG9(Y&_ZYEL]LUZ
M/^RK_P`%#/AY^UCXBU+P]I-UJWA[QIH<?F:GX5\2:=)I.M6*\?.UO+@LG(^=
M"RC(R1FNJ>!Q$(>TG!I+?^NASQQ5*4N521[M12!@PR""#2URG0%%%0:E,MM:
M-([!$C&YF/\`"!UI!?N?F+_P7X_:KD_MOP_\']+NML3(FN:\%;&X9(M86_X$
MK2D>T9KY1_91_9L\<?M):X;+P=H,^J);/LN;V1O)L;,]<2S$8#8.=B[GQ_#7
MLO[+O[&>I?\`!5?]L7X@?%GQ1->6'PXDU^9(9D)6;65A8116\3?P(D,<8=QR
M#E1\V67];?AM\.-%^$O@VS\/^'=+L=&T?3D\NVM+2(1Q1+]!W)Y)/))YS7VE
M;,J>78>.$H*\UK+U>_J>;2I2K3=66W0^3OV>O^"1&A^&;..Z\>^(+_Q%>@#=
M8:<[6-@GLS*?.D^N]%(_@KZF^'OP7\+_``GTT6?AK0M)T.WP`5L[5(B^.[$#
M+'W))KJ**^5KXRM6=ZDKG?&G%;"*-J@>E+117,6%%%%`!1110!\5_P#!9S_D
M1?`W_7_=?^BDK\\[_J:_0S_@LY_R(O@;_K_NO_125^>=_P!30!E7G4_2LFZ^
M^?K6M>=3]*R;K[Y^M`&5=_Q?Y[5!HOBO4_!>M1:CH^H7NEW]NVZ.XM9FBD0^
MS*014UW_`!?Y[5DWGWC0!]S?LG?\%B_&W@HV^G^.[=?&&E*`INU`BU&(=,[A
M\LGT8`G^]7Z+?`O]I#PC^T5X?%_X6U6&\"*#/;-^[N;0G^&2,\K]>A[$U^$?
M@SJGUKVGX0^+=4\">(+75=&O[K3-1M3F*XMW*.N>H]U/=3D'N*`/VNHKYL_9
M*_;JM_BFUKH/BT0:;XB<".WNDPEKJ1]!_P`\Y#_=)(/\)_A'TDC;U!Z4`+11
M10`4V;F%^<<'FG4C_</TII`?S!_\'"?Q*O/B)_P56^(<%S</-;^&%LM'LUW9
M6&-+6.1E`[?/*Y/N37J/_!,[_@WS3_@H=^RMIOQ+;XIMX4.H7MU9_8!X?^V!
M/)D*9\SSTSG&?NUX%_P6]_Y2L?&G_L-K_P"D\-?M3_P;._\`**GPU_V&]4_]
M*&K]4S+&UL#DU&>%ERMJ/1/=7Z^A^?9?AJ>*S6M#$+F2YG^-CY5_XA#8C_S7
MEO\`PD?_`+KH_P"(0V'_`*+RW_A)?_==?M517Q:XJS3_`)^_A'_(^G_U>R__
M`)]K\?\`,_%4_P#!H="!C_A?+G_N4O\`[KK\Q/\`@HA^QX/V#OVL?$7PQ&OG
MQ-_8,=N_]H&T^R^=YL"2X\O>^,;\?>/2OZY3R#7YK_M^_P#!NAHW[>7[4OB#
MXG7OQ3U3PW<:\ENC6$.BQW*0^5"D7#F52<[,].]>SD?%M95W_:%3W+=EOTV5
MSR\UX<I.BOJ<$I7[O;YLW/\`@V4^)U[\0?\`@F7IUA?3O._A37+[28"Y)*P9
MCG1?HIG8>P`%?H97S9_P2_\`^"=EG_P31^`M]X$L?%%UXLAO=6EU7[9/9K:L
MIDCB39L#-P/+ZY[U])U\GF=:E6Q=2K1^%MM'T>7TZD,/"%7XDE<_+C_@Z_\`
M^3#O"'_8Y0?^DMQ7YR?\&V'_`"EE\%?]@O5O_2&:OT;_`.#K_P#Y,.\(?]CE
M!_Z2W%?G)_P;8?\`*67P5_V"]6_](9J^^RG_`))VKZ3/C\T_Y'-'_MW\S^F*
MBBBOS,^["O$O^"DG_)@'QN_[$76/_2*:O;:\2_X*2?\`)@'QN_[$76/_`$BF
MKHPG\>'JOS,J_P##EZ'\D>@?\ARS_P"N\?\`Z$*_M(3[@^E?Q;Z!_P`ARS_Z
M[Q_^A"O[2$^X/I7W7'OQ4?\`M[_VT^-X.^"I_P!N_J+7Y4_\'9G/[%O@#_L<
M5_\`2.XK]5J_*G_@[,X_8M\`?]CBO_I'<5\QPY_R,Z/^+]&?19W_`+C4]&?@
MSX+\3:Q\/?$>F^(]%N;O3=1T>\2XL[Z`E&MKA"&1E;^\,9_"OZC_`/@D+_P4
M6TW_`(*-_LO6?B)WMK?QEH833_$UA&<>1=!<B55[12@%E]#N7JIK\1_^"57[
M!,W_``4%_8R_:4\-Z6J-XN\,S>'=<\.[B%$ERJ:JKP$]A+'\OIN"'M7DW_!-
M3]N;Q)_P3)_:ZM/$;P7JZ7YQT?Q5HT@*//;;\2*5.`)HF&Y2<$%2O`8U^@9[
M@J69PJ4J=O:TMN[32=O1_F?&Y/BI8%TZD[NG4_!IVO\`UT/ZOJ*YWX4_$_1/
MC)\/=%\3^'+Z'4]"UVSCO;&[A8%)XG4,K#\#R.QR#R*Z"1Q$A8]!7Y+*,HOE
MDM3]&335T$F`IST(YK^;?_@X'_X*5/\`MK?M+KX&\*WSW/P^^'EP]I;-`VZ/
M5[_[DUQQ]Y5(\N,^@8C[]?IC_P`'"W_!3$?L=_LWCP/X7O3!\1/B/;2VL31O
M^\TJP^Y-<\<JS9,<9]=Y_@K\CO\`@D/^P/J7[4_C;Q?X\O;5QX)^%6B7FKW5
MPZ?)=WR6LCVMNN>I#J)&]%3G[PK[GA?`TZ%.69XG1+2/KM=>?1'RF?8N=:K'
M`4-WK+T_K<^7/@H#_P`+B\)GG_D,V?\`Z/2O[*XO]4OTK^-7X*C'QC\)^G]L
MV?\`Z/2O[*HO]4OTK;CQ>_1])?H8\(_PZO\`B7Y#J_(__@[C_P"3:?A+_P!C
M1<?^DC5^N%?D?_P=Q_\`)M'PE_[&BX_])&KYSAG_`)&='U?Y,]O/O]PJ>GZH
M_*;_`()=_L*0?\%%/VI[?X;S^))O"T<VEW6H_;H[,73#R0OR["Z]=W7/:OTH
M'_!HIIA_YKA?#V/AI/\`Y)KY7_X-C6V?\%1K`XS_`,4SJ7\HJ_I#2Y`0#*\#
MU/\`A7T_%>=XW"8WV6'G9<J>R>_J>!D&5X3$83VE>%W=_AZ'XR?\0B>F?]%Q
MO?\`PFD_^2:7_B$5TQ>OQOOC_P!RTG_R37[-_:AZK^9_PI#=J.Z_G7S/^M>:
M=:OX1_R/:_U?R[_GW^+_`,S^8'_@K1_P1SUS_@EV_A;4'\5VOC+PWXK>:W@N
MUL393VT\2JQC>/>X(96RK!OX6!`XS[;_`,&J7Q"U'0/V]O$_A^&:3^S-?\(W
M$MS"3\AEAN+=HY,>JAY!]'-?27_!W%XGL7^#/P>TK[3$-1?6[ZZ6WW?O#$L"
M*7QZ!F4?4U\J_P#!K5IMQ=?\%(=3GBAD>&S\&WSS.!Q&#/:J,_4L!^-?;+&5
M<7P_.KBM96>O?6R/FUAJ>'SJ%.AI&ZT^1_1;&,(.U*_W#]*2'F/\3_.E?[A^
ME?E4%;0^_9_'9^UG_P`G4_$S_L:]4_\`2R6OT?\`V//^#96/]J_]F+P1\1C\
M8VT(>,=)AU,6'_"-BX^S;QG9O^TKNQZX%?G!^UG_`,G4_$S_`+&O5/\`TLEK
M^GG_`(([2"+_`()A_!#//_%)VG3Z&OUCB/,L3@\%1GAI6;LMD^E^I^=Y!@:&
M)Q52->/,EK^)^>'_`!"'1$_\EY;G_J4O_NNC_B$-A_Z+RW_A)?\`W77[2BZ7
M%#7:J,X-?%/BG-5_R]_"/^1]7_J[E_\`S[7X_P"9^+1_X-#8?^B\M_X27_W7
M7??LK?\`!L,G[+O[2W@7XAI\9#K9\&:S;:O]A/AK[.+KR9`_E^9]I;;G&,X-
M?K6C[UR.E+6=3B;,JD'"=31Z/1?Y%0R'`0DI1IJZ]?\`,1>G?I7C/_!1[_E'
MG\=_^R>Z_P#^FZXKV>O&/^"CW_*//X[_`/9/=?\`_3=<5X^#5JT%YK\STL3_
M``9^C_(_D8TRT^WZA;P;MGGR+'NQG;EL9K]JK;_@T=TRZMTD'QNOUWJ&P?#2
M<9'_`%\5^+7A_P#Y#MC_`-?"?^ABO[/]'_X\(_\`<7_T$5^G<79IBL&J7U:7
M+>]]$]FNZ/@N&<NP^*C4]O&]K6WZGXT_\0B>F_\`1<+[_P`)I/\`Y)I/^(13
M3`1GXWW_`"?^A:3_`.2*_:&BOB_]:<T_Y^_A'_(^I7#V7_\`/M?C_F?S!_\`
M!6?_`((Q:[_P2^L_#FM#Q9;>-/"OB2Y>RCO%L393V=PJ;Q')'O<$,H8A@W\#
M9`XSZ/\`\&NGC?4/#W_!2:?2+>9EL/$'A>]CNXLG:_E-%+&V/4%2![.:^X?^
M#LCG]B;P+T./&4?_`*1W%?!'_!LC_P`I2M'_`.Q=U/\`]%K7VE'&5<;D%6KB
M7=VDNVQ\S/"4\+G5.G0T3:_$_I*!YQ22]%_WA3J;+T7_`'A7Y5>ZN??/8_D3
M_P""BW_)_OQJ_P"QXUC_`-+9:_HH_P""`'_*(?X.?]>NH_\`ITO*_G7_`."B
MW_)_OQJ_['C6/_2V6OZ*/^"`'_*(?X.?]>NH_P#ITO*_2^+?^170]8_^DGP_
M#W_(QK?]O?\`I2/L:BBBOS4^Z"BBB@`HHHH`*_.W_@XP_;_/[*/['5SX+T2\
M^S^,?BBLFE6QC?$EK8``7<WJ-RMY0/K(2/NU^@GB36;7P[HMSJ%]/%:V=E&T
M\\TK;4AC12S,Q[``$GV%?RI?\%3/VS]0_P""B/[<FO\`BBQ6YN-'-RNB^&;-
M,L5M(VV1%5_O2N6D(QG=+CM7TW"V5_6\7[2:]V&K_0\+B#'?5\,XP?OST7ZG
M'?LY_L+>.?VG/@C\4?'OANS,NB_"K3H]1U'*$M=;GRT<78LD*R2L.<*@_O"O
MH_\`X-\?V^Q^QS^V5;>'=;O?L_@?XF-#I.H>8_[JSNPQ%K<Y/``9F1C_`'9,
MG[HK]M?^"4O[!EC^Q!^PAX?\#WUG;3ZWJMN^I>)@R!A=7EP@\V-N/F5$"1#U
M$>>]?SS_`/!5[]B:Y_8&_;7\3^#X(I4\.W4O]K>'9N</8S,6C4'UC8-&?=,]
MZ^OPN;4LVG7P-3X6O=[Z:7^_4^:K9?4RZ-+&0UE]KY_\#0_K`HKXL_X(7?M\
MI^W1^Q7I4^JWJW'CCP6L>A^(`S9EN'C3$-T<\GS8QN)_OA_2OM.OS+%8:>'K
M2HU%JG8^\H5X5J<:D'=-7"BBBN<U9_,%_P`'#!/_``]E^)8[%-._](8*^>?V
M3?VKO'7[$/QNTKQSX(U";3-6LB/,@DW&VU"W;!:&9.-\;K^7!!!`(^AO^#A?
M_E+-\2\]/+T[_P!(8*]_\'_\$AY_V^?^"+_PJ^)?@*UB'Q4\+VVIV;VO`_X2
M.SAU.[58<D@"9`#L)X(^4]B/V.GC,/1RW#QQ2O":C'RU74_,ZF'JU<?6=!VE
M%MJW6S/UI_X)G_\`!2OP9_P4@^"=OK_AZ6.P\0:>JQ:[H<DH-QIDV#SCJT3$
M$HX&",@X(('TK7\@?[,_[2WQ!_8`_:(MO%/A>>ZT+Q/X>N6M[^PNHV5;A5($
MMK<Q$@E3C#*>01D$$`U_3#_P3(_X*<>"/^"D?P936M`8:9XETW;%KF@S2AI]
M.E/1@?XX6YVN!S@@X((KX3B'AZ6"E[>CK2?X>OEV9]?DV<QQ4?9U-)K?S/IN
MOGC_`(*S_P#*-;XV_P#8H7__`**-?0]?/'_!6?\`Y1K?&W_L4+__`-%&O!P/
M^\T_\2_-'K8O^!/T/YGO^":__*0KX(?]CSH__I;%7]<MO_J5^E?R-?\`!-?_
M`)2%?!#_`+'G1_\`TMBK^N6W_P!2OTK[+CS_`'BC_A_4^7X._P!WGZ_H/KSC
M]K__`)-6^)?_`&*>J_\`I))7H]><?M?_`/)JWQ+_`.Q3U7_TDDKXG#_Q(^J/
MK:GPL_CWM(?M%S''NV^8P7.,XR?2OV9\/?\`!I+'X@T&ROF^.KPF]MXY_+_X
M1/=LW*&QG[6,XSUK\:--_P"/^#_?7^=?V:_#W_D0=$_Z\(/_`$6M?J'&&;8O
M!>S^K3Y;WOHO+NO,_/\`AK+</BO:.O'FM:V_F?C8?^#0Z%5)_P"%\MQ_U*7_
M`-UUE>(?^#1758[5GTGXY:?-+CY8[OPL\:D^[I=-_P"@FOW`HKXR/%F:)W]K
M^"_R/J'P[E__`#[_`!?^9_,I^US_`,&]?[0G[*V@7FNP:7IGQ`T"Q4O-<^'9
M7FN(4'5FMG59,`9)*!L`$G%?//[%7[</C[]@CXTV?C'P/J<UK+"ZKJ.F2NQL
M]6A!^:&=!U!&<-U4X(K^NZ>'SACCT/O7\^/_``<U_L":-^SG\?-!^*/A:PBT
MS1OB4\\6J6L"!88=2B"LTB@<#SD;<1CEE<]S7T^1<1O,)_4<?%/F32??RMW/
M`S7(U@H_7,&VN7=?Y'[:_L2_M?>&_P!M[]G/PY\0_"\G^@ZS#BXMF;,NGW*G
M;+!)_M*V?J"I'!%>%_\`!<GQ3JMA^REX>\*:;J-QI$'Q3\;:/X*U.]@;9);V
M-W)(9]K=MRQ[/HY'>OSY_P"#3K]I^YT+XP>/?A%>7#MINO6(\1Z;$S?+%<PE
M(9\#U>)HR?\`KB*_7/\`;K_9&TW]MO\`9PUWP'J-[)I4UZJ76FZE$I:72[Z%
MA)!<*,C.UP,C(R"1D9KY3&8..79I[*?PIIKT?^7Z'T>$Q4L9@/:0^*UOGU^_
M]3\[/VV$\`?LR_MRWGA;5]&^-2?"GP)\*["[M=,^&^H75K#HQ6[G1KJY$,\2
MA"@P9&SEL9SUK!\>>$_&OPG_`&#OA?\`M`>()=8MO'_@KXC6\_@Z^U6]2[UJ
MZ\*W]VL4-A?7"$^=O@ER>3@=,9(KV#P)XU\?_`;XZ:SXE^/'P.^*7C?Q??\`
MA*+P->:KX$T^#7?#OB&SCG>07'E%HY8)9-Y#(XV\G@`XJM^RI^PE\0OV@M5\
M#:!XGT+Q1\/_`-G+X6ZZ_B7P[X;\574-QX@UFX5V>TMYEB!$-G;LQ*QR,[D`
M`\8V^G[:%.$74DK1M=WOS:--15]W^*WL<;IN;ER==E;;5:OT]?O/TYM\F%#G
MC%24R!/*B5?[HQ3Z^,5NA]&%87Q,\.7OB_X>ZYI>G72V-_J-A/;6URREA;R/
M&RJY`Y(!(./:MVH[N[BL+62>>1(885+R2.P544#)))Z`"J3L[H35U8Y#]GSX
M):/^SK\%O#/@G0X$ATWPU81V41"@-*5'S2-ZN[%G8]V8FNSI(W61`RD,K#((
M.012T2DY-RENP225D%%%%(84444`%%%%`!1110!\<_\`!8'PQJ?B?P3X*33=
M.O\`47AOKDNMK;O,4!C4`D*#BOS^U3X<>(H"V_0-<3'7=82C'_CM?N,R!NHS
M044]AQ0!^#&K>'-1LE8S6%["!D'?`ZX_,5SU]$T3?,K+GU%?T"36,-RI$D4<
M@/4,H-9&K_#'PUX@0K?^'M#OE/47%C%+G_OI30!_/W><%JR+P<D^M?O%XI_8
M=^$'C!'%]\.?"99\DM!8);L?^!1[37DWCG_@C7\$O%^]K32M:\/R/_%8ZG*X
M!]=LQD`^E`'Y+>#.J?6O6/!G\-?6?BS_`((7_P!D%Y/"7CEI-IRD&K6>,^WF
M1G_V2O,O%/[`GQ2^#FZ6\\-2ZK8Q];K27%XG'4[%_>@>Y04`4?"<:R*`PROI
M7VU^R+^TY/K8M?"OB6Y:6^(":;?R'F\`'^JE/_/0`<-_&,]P=WQ-X3S%.\3@
MI+$=KHPPR'T(/(/UKU3PG`MU&HWNC+@I)&Y5XF&"&4CD,"`01R"!0!^B(8$D
M#M2UYY^SI\67^)/@YH=0=1KFDE8;U0-HFR"4G4=E<`G`Z,&':O0Z`"D?[A^E
M+2/]P_2FMQ,_E6_X+>_\I6/C3_V&U_\`2>&OVJ_X-G/^45/AK_L-ZI_Z4-7X
MJ_\`!;W_`)2L?&G_`+#:_P#I/#7[5?\`!LY_RBI\-?\`8;U3_P!*&K]*XB_Y
M$E#_`+=_])9\-D?_`"-ZWI+_`-*1^@%%%%?F:/N@HP,YQS2-G:<=>U?*_P"T
M-_P6;_9W_9/^+FI^!?B!\0'T+Q/I*Q/<V?\`8&I77E"1`Z_/!;NARK`\,>M;
M4:%2M+EI1<GOHK_D9U:\*4>:I*R\]#ZIQ17E/[)'[9?P^_;?^']QXL^&NOMX
MC\/VMY)I\ER;"XL]LZ!6*[)XT?A77G&#FO5JFI3G3DX5$TUT94)QFN:+NC\N
M/^#K_P#Y,.\(?]CE!_Z2W%?G)_P;8?\`*67P5_V"]6_](9J_1O\`X.O_`/DP
M[PA_V.4'_I+<5^<G_!MA_P`I9?!7_8+U;_TAFK])RG_DG:OI,^&S3_D<T?\`
MMW\S^F*BBBOS,^["O$O^"DG_`"8!\;O^Q%UC_P!(IJ]MKQ+_`(*2?\F`?&[_
M`+$76/\`TBFKHPG\>'JOS,J_\.7H?R1Z!_R'+/\`Z[Q_^A"O[2$^X/I7\6^@
M?\ARS_Z[Q_\`H0K^TA/N#Z5]UQ[\5'_M[_VT^-X.^"I_V[^HM?E3_P`'9O\`
MR99X`_['%?\`TCN*_5:ORI_X.S?^3+/`'_8XK_Z1W%?,<.?\C*CZ_HSZ+._]
MQJ>C/(_^#090]Q^T$"`0?^$<&#_W%:Q_^#E;_@E4_A+5I?VA?`^FJNG:E*L?
MC&TMX_\`43L<)?X'\+G"2?[11N=S$;/_``:"?\?/[0/U\.?^Y6OV6^(O@72_
MB9X,U+P_K=A;ZIH^LVTEG>VDZ;X[B)U*LK#T()KV,TS*I@<]G7AMI==URK0\
MO+,##%Y/"C/SL^SNS\/?^#:7_@J6/AIXTC^`/CG4MNA:],\OA.[GD^2QO&^9
M[/)Z),<E/23(_C%?M'^T1^T%X:_9G^"7B3QYXJO19:#X9LGO;F0\,^T96-`>
MKNV%4=V8"OYD?^"JO_!/S7_^"8W[6\^EV,E\OAC4)SJOA+5U+*YA#@B/>.DT
M+X4\YX5N`PKIO^"@?_!9OQU^WM^S)\._AUJZ26`\/P>9XFN4D`7Q%?(62&4@
M=%6,!R#QYCL?X5KU,PX>IYA7I8W"/]W/67E_P^WDSBP>=3P=&>&Q7QP^'S_K
M\CSGXL>//B-_P5\_;Z>YM;:2^\3^/]36QTJQWDPZ7:@XCCS_``Q11Y9FQV=N
MIK^B#X<_L7^'?V#/^":/B?X=^'8XY(],\):E)?7VP+)JEV]JYFN'[Y9N@/10
MHZ"OE?\`X-O?^"7S?L[?"$?&;QAI@B\9^.;<+H\,R8DTG3&Y#8ZB2?ACW"!!
MW85^A_[5W_)LGQ$_[%?4_P#TEDKR>(<UC4KPP6&TIP=O5K_+8]+)LME2IRQ5
M;6<_P1_(I\%?^2Q^$_\`L,V?_H]*_LJB_P!4OTK^-3X*?\EC\)?]ABS_`/1Z
M5_97%_JE^E>AQ]_%H^DOT.#A#^%5_P`2_4=7Y'_\'<?_`";1\)?^QHN/_21J
M_7"OR/\`^#N/_DVGX2_]C1<?^DC5\WPS_P`C.CZO\F>YGW^X5/3]4?AIX'\?
MZ]\-M=&I>&];U?P_J2QF,76FWDEK.%.,KOC(;!XR,]J[#_ALGXO*?^2J?$;C
M_J9+W_XY7UM_P;4>'M/\5?\`!3BQM=3L;/4;5O#6I,8;F%98R0(\':P(SS7]
M%D7P3\&F-2?"?ALD@?\`,-A_^)K[W/>(J6!Q7L945/1._KTV9\AE&2U<5AU5
MIU7%7>FO^:/Y'?\`ALKXO9_Y*I\1O_"DO/\`XY1_PV3\7F/'Q3^(WX>)+S_X
MY7]<G_"DO!O_`$*?AK_P60__`!-'_"DO!N,?\(GX:_\`!9#_`/$UXW^NM'_H
M&7WK_(]/_5C$?\_W^/\`F?Q[ZOXWU/XJ^,K2Z\:>*-<U#S'6.;4;V634;B&/
M/)`D?<V.N-PK^B#_`(-[_P!E#X'_``=_9^OO%_PN\8I\1-=\2A+?7-8EMOLL
M]DR886?V=LO"%)W?,3O.&R1C'SC_`,'4_P"R/X%\"_"#X??$?P]X9TG0M?GU
MQ]$O[C3[9+?[?%);O*GFA0`[*83AB,@,1GI7SE_P:Y_&O5O`_P#P4*O/"-O=
MS#1O&_AZZ2YMLYC::WVS12XZ;E`D4'TD->AF=;^TLF>)H7@E=N/>W3]4<N!A
M]0S-8>K[[E:TNJN?T5``#`XI'^X?I38'+Q@GJ1FG/]P_2ORY'WC/X[/VL_\`
MDZGXF?\`8UZI_P"EDM6_"W[97Q@\#^'K/2-%^*GQ'TC2M.B$-K967B6\M[>V
MC'1$C20*JCT``JI^UG_R=1\3/^QKU3_TLEK^DW_@D9\`/`GB7_@FO\%[[4?!
M7A._O;KPM:R37%SI%O++,Q7EF9D))]S7[)FV:T\!@Z52K3YT[*WR/S#+,NJ8
MO$3C3GRVU_'U/YS/^&]/CG_T6;XJ_P#A67__`,=K2\&_MV_'&Y\7:5&_QC^*
M;I)>0J5;Q7?D,"XX.9:_JP_X9C^&W_1/O!/_`(([7_XBA?V9?ANC!E^'_@I6
M4Y!&B6P(/J#LKYN7&.%<6OJR_#_(^@7#-=/6N_Q_S.K\/.9-'@)))**<GOP*
MNTV&%+>,*BA5'0"G5\`W?4^P"O&/^"CW_*//X[_]D]U__P!-UQ7L]>,?\%'O
M^4>?QW_[)[K_`/Z;KBM\+_'AZK\S#$_P9^C_`"/Y&-.N_L%_;S[=WDR+)C.,
MX;.*_:*T_P"#N."TMDC/P5N6*@#/_"2A>@Q_S[FOQ?TJU6^U.VA<D)-*J,1U
M`+8-?O#9?\&F/PDN[1'/Q,^(H+`$_N[/`R,_\\J_6N(9Y6E3_M%-O6UK_/9^
MA^<Y'','&3P+MM>]OEN<'_Q%VP?]$2N?_"F'_P`C4?\`$7=`#_R1*Y_#Q,O_
M`,C5RW[>W_!KNGP5^`&H>*?A!XG\2^,O$&B9N;K1M32$/>6RJ=_V<QHN95X(
M4YW`$#YL`_DOX'MM%M/'NGP^+8M830H[M8]433RD=]%%NP_EB12N\<G##DC'
M&<UY^!RG(<93=3#PO;I>5_NN=N+S+-L-45.M)*_DK??8^P/^"LO_``6C\0?\
M%0='\-Z$WA.U\'>&?#ER]^EJM\;V>[N63RP[N40`*I8!0/XCST`]*_X-;OAS
MJ7B?_@HM>Z_;P2MIGACPS=M>3A3M1IV2*)">@+?.1GJ$;TKZ4_9=_P"#</\`
M9J_:E^&6B^.O"'Q>^(7B7PQJJ"1&MWLHG5@1OBD_<%HW7HRD9!_"OTP_8G_8
M%^&7[`_PVF\-?#G0?[-@O95FO[R>5I[S4I%&`\LC<G&3A1A5R<`9->?F>>X"
MA@)Y?@HM-Z6::M?>]];G=@,HQ=7%QQN*DG;73KVVTL>U"FR]%_WA3@,4V7HO
M^\*_/->I]B]C^1/_`(*+?\G^_&K_`+'C6/\`TMEK^BC_`((`?\HA_@Y_UZZC
M_P"G2\K^=?\`X*+?\G^_&K_L>-8_]+9:_HH_X(`?\HA_@Y_UZZC_`.G2\K]+
MXM_Y%=#UC_Z2?#</?\C&M_V]_P"E(^QJ***_-3[H****`"@G%%8_COQE8?#_
M`,*ZAK6JW<5CIFE6TMW=W$I`2&*-2S,2>P`)HLVTD%TM6?F[_P`'+'[?!_9Z
M_93C^%VAWWE>*?BAN@N2CGS+/2T;]^WJ/-;$0]5,OI7Y\_\`!M]^P@?VI?VS
M$\=ZS9^=X3^%>S4\2)^[N=2))M8\]RC*93_US7UKYD_X*3_MG:A^WI^V%XM^
M(-S).-+NKDV>AVLG'V/3HB5@3'0,5^=O5Y&KZ<_X)L_\%Z[;_@F_^SA:^`M#
M^$%AK-P]Y-J&I:K+KC02ZC<2'`=D$)VA8U1`,GA<]2:_5:>4XG"9/]6PT+U9
M_%Y7_P`EI^)^>3S*A7S+VN(E^[AM\MO\S^CN&+RX=I`QSQ7YS?\`!R1^P9_P
MU#^R"GCS0K%9?%_PK\S408T_>7>FL!]JBXY8IM24#MY;X^\:^8/^(O#6/^B)
M:7_X4<G_`,CU7U/_`(.V]0UFQFMKKX&Z1<6]Q&T4D;^(I"LBL,%2/L_((KYG
M`</YOA<1#$4Z>L7W7W;GO8S.\LQ%&5&=31^3_P`CXP_X(E?M\R?L'_MJZ-?Z
MG>20^"?%X71?$*ECY<44C#RKDCUBD()/78T@[U_499WT=Y#$T;K(LB!U93D,
M",Y![U_&7\0-<TWQ'X[UG4=%TO\`L+2K^]EN++3O.\[[!"SEDA#X&X("%!(!
M.*_HO_X-V?\`@H"O[7/['UOX2UV^\_QM\,$32KSS&S)>66,6MQ[X1?*8]=T6
M3]X5Z_&N6.48YA!=E+]/\G\CS^%\P47+!R?G'^OQ^\_0RBD1@ZY!R#2U^<GV
MC/Y@O^#AG_E+-\2_^N>G?^D,%?LS_P`&Y\:O_P`$B_AAD`XFUCJ/^HM>5^,O
M_!PS_P`I9OB7_P!<]._](8*_9S_@W-_Y1%?#'_KMK'_IVO*_0^(?^1%AO^W?
M_26?$Y1_R.*_S_-'E7_!<3_@AY:?MAZ+J/Q/^&5A::?\4K"+S+NRC`BB\41J
M/NMV6Y`&%?\`C`"L>%(_#7]G;]HGXA_L#_M"6OBCPM=7_AKQ;X=N6@N[.XC:
M,2J&Q):W$1P60D892.V1@@&O[`'0.N#TK\U?^"WG_!$"P_;6T2[^(WPUL;;3
M?BMID&ZX@4B*'Q/$@XC<]!<`9"2'&[A6XP5X.'>(8P7U+':TWHF^GD_+\COS
MG)I2E];P>DUJTNOIYGT=_P`$R?\`@IYX)_X*0?!5=<T64:;XHTQ4CUW099`9
M].E(X9?[\+8.U\<]#@Y%:W_!6?\`Y1K?&W_L4+__`-%&OY@_@#\?_B+^P;^T
M%!XC\,7>H^%?%_ARY:"\M+B-HPX5L26MS"?O*2,,C=",\$`C]W=:_P""FGA3
M_@IM_P`$=OC1JVC-%I?B[2O!M['X@T"1\RV$OD-ET/5X6()5QZ8.#D4\SX>>
M#Q5/$4-:4I+SMJOP[,>79TL70G1JZ5$G\['X>_\`!-?_`)2%?!#_`+'G1_\`
MTMBK^N6W_P!2OTK^1O\`X)K\?\%"O@A_V/.C_P#I;%7]<EO_`*E?I6_'G^\4
MO\+_`#.?@_\`W>?K^@^O./VO_P#DU;XE_P#8IZK_`.DDE>CUYQ^U_P#\FK?$
MO_L4]5_]))*^)P_\2/JCZRI\+/X^=-_X_P"#_?7^=?V:_#W_`)$'0_\`KP@_
M]%K7\96F_P#'_!_OK_.O[-?A[_R(.A_]>$'_`*+6OT#C_P#Y<_\`;W_MI\;P
M=M5]5^IL4445^<GVH5^8'_!U;HUO>_\`!/WP_=2;1/9>,K5HL\DEK:Y4X_"O
MT_K\<_\`@[0^/-C9?"KX:?#6&XCDU34=5F\0W,2L-T4$,;P1DCT9Y7P?6(^A
MKW.&Z<IYG145U/*SR<88&JY=OS/AC_@W3UB?2/\`@K3\.$A)"WD&IP2#LR&P
MG)_50?PK^G,C-?S>_P#!L/\`"^X\<?\`!3BPUM(F:U\':!?W\LFTE5:5!;(#
M]?.8CZ5_2$.17I\:R3QZ\HK\V>?PI&2P3;ZR?Z#!;Q@_<3GVIRQJAR%`/L*6
MBOD#Z5!1110`51\2Z1'X@\/7UA,H:*^@DMW!&?E=2I_0U>H/-`'CG[*OQ8:^
M\.V?A'69676](A,$+RGF^CBRC`'O)&5*L.IVAOXN/8\XKY2_:+\(MX-^*-ZJ
M-)##J+#5]/EB.QH)<@2[&'(99/GS_P!-A[BMCX7_`+;#>'BNG^-HGEB4[8]7
MM8LG'_3:(#@_[29!_NK0!]*T5F^%O%^E^-]*CO\`2+^SU*RE&4GMIEE1_H03
M6E0`4444`%%%%`!1110`4444`%%%%`!1110`4C*'&",BEHH`XOXF_L^>$/BU
M"QUO1;:>Y`PEW$/)N8_<2+AOP)(]C7@/CS]C_6_AB\E[H,LWB32E^9H2@%_`
M/]U0%F&.RA6_V6-?65!&10!\F?!GQDGA'Q?IFLPRAK&5A8WY7H(9&QN8>L<@
M!.?N@R#C)KZS'3TKQ[X_?`R*^M+W7M(@;[9)&W]I6D(P-1C*X9U':91R"/O`
M;3GY2O;_``4\7_\`"=_"[0M4:59Y;FS7SI%Z/*OR2$?\#5J`.JILAQ&QR!@=
M3VIU)(F]&7U&*`]3^5[_`(+FZ=)IG_!5WXS)(.9-6AF7W5[2!P?R-?K=_P`&
MZ/[1/@/X<?\`!,7P[IFO^-?".B:C'K.I.UK?ZO;VTRJ;AB"4=@P!'/2O&O\`
M@X+_`.",'Q!^/?QT7XR?"G2?^$GDU2QBM=>T:W9$O%FA&Q)XE8CS`T852H^8
M&,$`[N/RDU;_`()^?';0;TV]W\'?B7!<)U1_#=X"/_(=?JL8X7-<KI47547%
M1OMNE;9M'YZYXC+\PJ5HTW)2O]S=_,_JJ'[8WPI(_P"2F?#W_P`*&U_^+H_X
M;%^%'_13?A[_`.%#:_\`Q=?RE_\`#"?QL/\`S2/XD?\`A.7?_P`;H_X82^-G
M_1(_B1_X3EW_`/&Z\W_4W!_]!*^Y?YG?_K/B?^@=_C_D?U9M^V-\*?\`HIGP
M]/\`W,-I_P#%U_.%_P`%]?&>D^/O^"HOC_5-#U33]8TVX@T\175C<)<0R8LH
M0<.I*G!R.#7A/_#"?QMZ?\*C^)'_`(3EW_\`&Z[OX+_\$BOVD/CKXEM=.TGX
M1^,;!;EPC7NL6$FFV<`)P6:68*,#T&3Z`UZF49/A,KJ2Q"Q">ENB_4\_,LSQ
M./IJC[%K6_5_H?LE_P`&K%E+;?\`!.C6)9$VQW'C"],9/\0$%L"?SR/PK],3
M7@7_``30_8X@_8-_9`\)_#9+J*_O=)@>?4[N($)=WDSF29U!YV[FVKGG:BU[
M[7YQF^)C7QM6M#9R=C[?+Z+I8:%.6Z2/S!_X.LM*EOOV`?#=R@S#9>,;4R'!
MXW6UP!7YC_\`!O+XVT?X<_\`!4CP=JNO:KINC:9#IFJK)=7UREO"A:RE"@NY
M"@DG`YK]]_\`@IG^Q/!^WW^QUXN^'37<.GZEJ$27>E7<L>Y+:]@;S(2W<*2"
MC$<A7;%?S<_&7_@DA^T;\#?$-U8:O\(_&5XMJQ47NE:?)J-G,,D;EEA#+@^A
MP?4"OM^&,1AZ^5U,#5FHR=]^S/D\^H5J6.AC(0;2M]Z/Z>_^&Q?A1_T4SX>_
M^%#:_P#Q='_#8OPH_P"BF_#W_P`*&U_^+K^4O_AA+XV?]$C^)'_A.7?_`,;H
M_P"&$OC9_P!$C^)'_A.7?_QNL_\`4W!_]!*^Y?YFO^LV)_Z!W^/^1_5I_P`-
MB_"C_HIOP]_\*&U_^+KQS_@H5^U3\-/$?["GQDL;#XA^![V]O/!6K006]OKE
MM+),[6<H554/DL2<`#K7\UW_``PE\;/^B1_$C_PG+O\`^-U);?L$_&^ZE6./
MX0?$J1VX"KX<NR3_`.0ZNEPAA(5(S^LK1WV73YD5.)<3*+C[!J_K_D>=>"=,
M?6/&&D6D7S2W=[#"@'JTB@?SK^SV,YC7Z5_/'_P2-_X(1_%SQW^TMX4\:?$[
MPCJ'@CP/X3U"'5I(-8C\B\U:2%M\<*0'YU4NJEF<#"YQDGC^AU/NCZ5YW&N/
MHXBM3IT9*7*G=KSM_D=G"N#J4:4Y5%;F>E^R%K\J?^#LW_DRSP!_V.*_^D=Q
M7ZK5^97_``=!_"/Q7\9/V1O`^G>$O#>N>)KZV\5K<2V^EV4EW+'']DG7<RQJ
M2!D@9/<UX?#TDLQHN3MK^C/7SF+E@JBCJ['@?_!H)_Q\_M`_7PY_[E:_;&OQ
MW_X-5O@9XV^"-S\=/^$P\(>)?"_]I_V`;3^U=.FL_M/E_P!I[]GF*-VW>F<=
M-P]:_8BMN)YQEF=5Q=UI^2,.'H2A@*<9*SU_-GS9_P`%2/\`@GQH/_!1/]EC
M6/!]\(K7Q#:YOO#NILHW:?>J#MYZ^6XRCCNK9Z@5^,O_``2)_P""(/CGXP?M
MH-_PN'P5KWAWP3\.[H7&I1ZE9200Z[<1R$1VT3,`LL3,A9V3(*#&?G%?T6XY
MI`,5E@<_Q6%P\\-3VE]Z[V_KS-L5E%#$5X5ZBUC]S]2*QL8].MDAA54BC`5%
M4`!0!@``=@*X3]J__DV7XB?]BOJ?_I+)7H-<%^U%97&J?LZ>/+2T@ENKJ[\.
M:C###&I9Y7:VD"JH')).``/6O)HV]I%ONCT9_"S^0_X*?\EC\)?]ABS_`/1Z
M5_97%_JE^E?R3?!_]A[XS6'Q9\+SS_"CXBPPPZO:.\C^'KM511.A))*8``R?
MPK^MB!MT*\$''0]17W/'5:%2I2<))[[/T/D^%*,X4ZJFFO>0^OR/_P"#N/\`
MY-H^$O\`V-%Q_P"DC5^N%?EI_P`'2_P;\6_&?]GKX7V?A'PQK_B>ZLO$<\\\
M6E6$MV\*&V90S",$@9XR:^=X<G&.94G)V5W^3/:SR,I8&HHJ[M^J/SR_X-L/
M%>E^"_\`@II87NL:GI^DV8\-ZDAN+RX2"(,1'@;F(&3Z9K^B2+]HOX>B-1_P
MG?@W.!_S&K;_`.+K^34?L)_&P'_DD7Q(/_<N7?\`\;H_X82^-G_1(_B1_P"$
MY=__`!NON\YR+#YA7]NZZCHELNGS/D,KS?$8.A[!46];]5O\C^LS_AHSX>_]
M#WX-_P#!U;?_`!=))^T;\/E1B/'?@W(&?^0U;?\`Q=?R:?\`#"7QL_Z)'\2/
M_"<N_P#XW1_PPE\;/^B1_$C_`,)R[_\`C=>2N#,-_P!!*^Y?YGH_ZS8G_H'?
MX_Y'ZJ_\'3/[9G@3XE_"3P#\-_#'BG1/$.N6FNR:UJ$6F7D=TMC''`\2"1D)
M"LQE;"YSA2<=,_)O_!M5:2S_`/!5;PQ(BDK;:+J<CG^ZOV<KG\V%>!?#O_@E
MI^T5\4]4BM-'^#/Q!9Y6"^9=:/-9P)G^]+,%11]2*_;#_@A)_P`$8-5_X)_+
MJWCWXA3V,WQ$\16(L(K&U830Z):,ZR.ADZ/,[*FXKPH3`)R37HXVK@LKRF>"
MA54I236EKN_ET./#4\3F&8QQ,H<J5OP/TEMQ^Z&.F.*<_P!P_2DBC\J-5ZX%
M$S;(7/H":_+EN??,_CM_:S_Y.I^)G_8UZI_Z62U_2C_P2*^.?@GP]_P36^"U
ME?\`C#PM8WEMX6M(YH+C58(I8F"\AE9P0?8U_/\`?M0?L2_&/6OVEOB'>6?P
MK^(5U:W?B;4IX98O#]TZ2HUW*592$P5(P01UKA?^&$_C;_T2/XD?^$Y=_P#Q
MNOV#,\OP^8X2E2E64>6SZ/I;NC\UR_%5\#7G-4G*^G5=?0_K,_X:,^'I_P"9
M[\&_^#JV_P#BZ/\`AHOX>_\`0]^#?_!U;?\`Q=?R9G]A/XV$_P#)(_B1_P"$
MY=__`!NC_AA+XV?]$C^)'_A.7?\`\;KY[_4W#?\`02ON7^9['^L^)_Z!W^/^
M1_68?VB_AZ/^9[\&_P#@ZMO_`(NI;+X_>!-3O8;:V\:^$KBXN'$<446L6[O(
MQ.`J@/DDG@`5_)=_PPE\;/\`HD?Q(_\`"<N__C=>F?L7_L6_&#PW^UY\+M0U
M#X6_$"RL;'Q9IEQ<3SZ!=1QPQI=1LSLQ3`4`$DGI6=7@_#0@Y+$IV79?YFE+
MB3$RFHN@]7Y_Y']6(.37C/\`P4>_Y1Y_'?\`[)[K_P#Z;KBO9DY4'CIVKR+_
M`(*!Z+>>)?V#OC5ING6ES?ZAJ/@36[6UMK>(RS7$KV$ZHB*.68L0`!U)KXO"
MM>V@_-'U.)3]E)>3_(_D4\/_`/(=L?\`KX3_`-#%?V?Z/_R#XA_L+_Z"*_D6
MT/\`85^-4.MV3-\)?B,JK.A8GP[=@*-PY/[NOZY]%8MI\>5*G8N0?H*^XXYK
M4YJBH-/XMOD?)\)4IPC4YU:[7ZEB:U6<8.?P[U^,'_!P!_P1)_M@:Q\=?A'H
MS"[3==>+-!M(L_:`,EKZ!!_'CF1`.>7'(;/[1U%=VJWENT;A2K\$$9!'I7Q^
M6YE5P-95J/S7='TV.P-/%TG2J_\`!7H?RM?\$M/^"IGC'_@FA\9%O;$S:SX'
MUB9%U_0)),1W*CCSXL\).@Z-T;[K<8Q_39^S3^TMX/\`VM/@YI/CKP/J]OK.
M@:Q'NCECX>%\#=%(O5)%/#*>0:_&/_@NO_P0IU'P3XQNOBO\$O#]WJ>C:S/G
M7/#6F6QDEL+ASS<6\2<M$Y(W(!E&.1\I^7Y]_P""7GQ6_:>_X)K?&!=4TSX2
M?$[6?!NJR(NO^'WT&\6.]C'_`"UC)CQ'.H)P^.>A!!X^WS7!X3-Z"QV&DHU.
MJ;M?R?GYGRN7XC$Y=7^J5TY0Z-7T_P"`?TN#FFR]%_WA7-_!_P"*EC\:?AWI
M7B73;74[*TU6W6=;?4;1[2[MR>L<L3@,CJ<@@]QW'-=#=2>6JG&?F]<5^<N+
M3Y7NC[6]U='\B_\`P45&?V_OC5_V/&L?^ELM?O;_`,$+OVE_A]X"_P""5'PD
MTG6O'7@W2-3M;:_$UI>ZS;P3P[M2NV&Y&8$9!!Y'0BOQ<_;X_8Q^+_BG]N#X
MO:GIOPN\?WVGZAXQU6XMKBWT&ZEBGC>[D975@A#*00017DO_``PK\;=N/^%1
M_$C_`,)R[_\`C=?L&/P6&S'!4:4ZJC9)]'TMW/S;"XJO@L94JQI.5VUU6[]#
M^K/_`(;%^%'_`$4WX>_^%#:__%T?\-B_"C_HIOP]_P#"AM?_`(NOY2_^&$OC
M9_T2/XD?^$Y=_P#QNC_AA+XV?]$C^)'_`(3EW_\`&Z\+_4W!_P#02ON7^9Z_
M^L^)_P"@=_C_`)']6G_#8OPH_P"BF_#W_P`*&U_^+K7\#_M"^!_B7KO]F^'O
M&7A37K_RS+]FT[58+J8(."VU&)P"1SC'-?R:?\,)?&S_`*)'\2/_``G+O_XW
M7Z`_\&U_[,GQ&^$/_!1B75O%7@/QAX;TQO"=_;B[U+2)[6'S&EMB$WNH&XA3
MQ[5PYCPMAL/AIUH5U)Q5[::_B=.#S_$5J\:4J+2;WU_R/W[+X4FORI_X.=_V
M_C\(/V?=-^#6@7HC\1?$/,VKF)L26FEQMRAYR#-*`ONL<@[U^H_BCQ'#X4\/
MWVHW"3/!86[W$@AC,DC*JDD*B@ECQP`,FOY<_P!N[P/^T)^W'^U7XL^(VJ_"
M3XF1?V]>$:?:OX>N\65FGR6\(^3^&,+GU8L>]</">!IUL7[:LTHPUU[]/\SL
MS_%U*>&]G25Y2TVZ&S_P1J_X)1-_P4Z^*'B2WUG4]6\.^#?"UBLEWJ-C'&TT
MEU*P$4"[P5^Z)')QT0>HK]%Q_P`&E/PJ(_Y*C\0?QBLQ_P"TZ^P_^".G[$47
M["'[$GA;PM<VJP^)]6@76?$4A`WM?3JK-$3Z1+MB'_7//>OJJM\UXIQCQ4_J
MM1J"T6VMNOS,LNX?PT:$?;0O+K<_)/\`XA*/A5_T5'X@_P#?JR_^-T?\0E'P
MJ_Z*C\0?^_5E_P#&Z_6RBO-_UGS7_G\_P_R.W^P\%_S[1^%'_!0G_@V>T3]F
M?]E'Q1X]^'OC#Q7XIUSPM"-0GTV_AM]D]HA_?LOEJ#N1#O\`<(PQG%?"?_!*
M;]N.\_8%_;+\,^,C)+_PCEW(-+\16XSB:PF8!V([M&VV5?=,=Z_JYU?1X-<T
MV>SNHXY[:YC:*:-UW+(C`JRD>A!(K^8/_@I1_P`$E/B-^S;^V1XR\/>"O`?B
M_P`2>#);K^T-#O-+TF>[A%K.2ZPED5ANB.Z,YY.S/>OJ^'<Y>/IU,%F$DW).
MS?GT^6Y\]G.5_5*D,3@XVLUMY?U8_IW\+:Y9^)O#ECJ.GW,-W8W\"7%O/$VY
M)HW&Y64]P0015^OSQ_X-X/C=\0M>_94;X;?$WPKXK\/ZW\.Y%M],N=8TV>U%
M_ISY,2JTBC<T3!D('1/+]Z_0UCM4G&<5\#CL*\-7E1;O9GV&'K>VI1J;7/Y@
MO^#AG_E+-\2_^N>G?^D,%?LY_P`&YO\`RB*^&/\`UVUC_P!.]Y7Y1_\`!=_]
ME#XH?$__`(*@_$/6?#GPZ\;:[I%TE@(;VPT6XN()2ME"K;71"IP01U[5^N'_
M``0#\#:Y\-/^"67PYT3Q'H^I:#K%I+JQGLK^V>WN(=VJ73KN1P&&58$9'0BO
MML_K4Y9+AX1DFUR_^DL^3RBE-9M6FUH[_FC[.ILD8DC93D!ACBG45\`?9GYN
M_P#!;C_@B-IG[;_ARX\?_#RTM],^+&F0$R1KMCA\2QJ,B*4\!9AC"2?\!;C!
M7\%/AG\4_&G[(/Q)\0V\,-WH^J3V%_X9U_2KR%XQ/!-&T,]O-&<$%2=PS]UT
M4CI7]AI&:_.;_@M9_P`$2M(_;E\)7'CKP'!9Z3\6M+A+9$8CA\1QJ/\`4S'^
M&4#A)#[*W!ROVG#G$:HKZIC=8/1/M_P/R/EL[R5U)?6<+I-;^?IY_F?AC_P3
M7_Y2%_!#_L>='_\`2V*OZY+?_4K]*_EJ_8%_8D^,7@+]OKX17>L_"[Q]IMGI
M'C?2Y+RXN-#N4AMDCO(][L^S:%`!);.,"OZE+4[H%/'2M..*L*E>E*#3]WIZ
MD<)TIPH5%-6U_0DKSC]K_P#Y-6^)?_8IZK_Z225Z/7GG[6-C<:M^S/\`$*SL
M[>:[N[SPQJ<$$,2EGE=K60*J@<DDX``]:^,H-*I&_=?F?4U/A9_'KI[!+Z`G
MH'7/L,U_7;X$_:_^%EMX)T>*3XD^`(WCLH597\06H92(UX(W\&OY8O\`AA/X
MV`<?"/XD?^$Y=_\`QND/["?QMS_R2/XD?^$Y=_\`QNOUW/<LPV9\G-64>6_9
M[V\_(_-\IQV(P#FE2<K^JV^1_5H?VQOA2!_R4SX>_P#A0VO_`,76-KW_``4$
M^!_A>"634/C'\++-8@2QF\4V28_.6OY9/^&$OC9_T2/XD?\`A.7?_P`;JWH_
M_!/;X[Z]<>3:?!SXF7$AP-J>&[LG_P!%U\__`*FX+KB?R_S/7?$V*_Y\?G_D
M?O1^UY_P<B?`#X`^&KR+P?K)^)_B949;>TT>-ULM_8R73`($]=F\^@K\"/VP
MOVM_&/[<?[0.L_$+QI<I/J^L2*D-M#E;>P@7B.WA4DD(HZ9)))))))->\_!+
M_@@7^U'\:K^!!\.;CPK9RGYKOQ%<QV*1#/WC'DR_DF:_5+_@FE_P;@^!?V4?
M$FG>,?B5JL'Q%\::>XN+2U%OLTC2Y1R'5&RTSJ<$.^`.R`@&NRC5R?)8.5.?
MM*C7>[]--$<]2GF>:24*L>2'I_3;-?\`X-Q_^"=^H_L?_LS7WC3Q78R6/C+X
MFO%=-;2KMET_3XP?L\3CJ'8O)(P]'0'E37Z/CI]*;!`((E0=%Z4^OSO'8VIB
MZ\L15WE^'9?<?:8/"PPU%48;(****Y3H"BBB@`HHHH`X#]HOX5R?%#P%(MDJ
M#6=+8W5@Q./,<##1$]A(N5SV)5OX:^)/$\HFB9BCHPRK*Z[60CAE([$'(([$
M&OT9<90@9YXXKYC_`&R_V;[EGNO%_AVV:;>-^K64:Y9\#'VB,#JP``=1R0-P
M&<[@#Y&C\:ZQ\.M;;4=`U74-&OLC?-:3-$90.@<`X<>S`BO0_!O_``5:\<^`
MT6'Q!INE>*;=``7_`./.Y(]2R@H3_P!LQ7E'BQ@X9E(96Y!!R#7F?B_HW^?6
M@#[^\#?\%D?A7K;QQ:]#K_ABXQAFGMA<6X^C1DL?Q05[)X(_;>^$GQ%"?V3\
M0?#$[R8`CEO5MY,GMLDVM^E?B5XLZL,G!'/-<@G$AQ@<]J`/Z*]+\1Z?KENL
MME?6EY$_W7@F616^A!P:N!P1WK^>3P[XAU#0V#V5]>6;CHT$[1L/Q4BO0/#?
M[3?Q(\/*HL?'_C6U1?X(];N0O_?._'Z4`?NV&ST!I:_%G1?V[OC#IZ!4^(GB
M5U7IYMQYO_H0-=-8_P#!1?XTQ(`/'>H$#GY[:V<_3F.@#]@**^%?^";7[7/Q
M$^.WQSO=(\5>(Y=7TZ'2);E8FM+>+$BR1*&RB*>`QXS7W50`4444`%%%%`!1
M110`4444`!&:Q_!'@>Q^'^D26&FH8K1[FXNA&3D1M-*TK!?1=SG`[#BM9Y%C
M(R<9Z5E^#_'.D^/]/GN]&O8K^VMKNXL)9(P=J3P2M#-'R!RDB.I]U-.SM<+F
MM0>1112`0J">@)%!4$Y(!-+118$)L&>@H\M?04M%`[B;!Z#\J"@(Q@&EHI6$
M(%`Z`>E+110DEL`$9%-$8`Z#&.G:G44-)[@)L'H*/+7T%+13'<3RU]!1L'H/
MRI:*/4+C3&,?=7\J<!@444K(+A2%<]<9I:*+"L-\I?[J_E3J**86"BBB@`I"
M`>P-+10#0FP>@I0`HP,`444@"D**QY`/X4M%,!-@]!1Y:^@I:*-1W$\M?04;
M!Z#\J6B@5QIC&1@#BE"!6)`'-+10&H4$9%%%`#1&!C@8'M2[!Z"EHI+0!-@S
MT%&P>@I:0L!3N%P*`]A08U/\(_*ESFB@$P`P.*1EW#!`(]Z6B@!OE*.<#-*J
M[1VI:*'KN`4444)@-,8;.0.:41@#&!2T4!=B*@4D@`$T$;AS2T4/4$-$:C^%
M?RI=@'84M%+Y@)L`["C8/04M%/4=Q-@ST%&P9S@?E2T4"8FT>@I#&.>!D^U.
MHH!:"*@3H`/H*6BBBW8`HHHH`*:(5!S@<^U.HH`;Y2[@<#(]J<1GTHHI"2L)
ML'H/RH"@'(`I:*=AA1110`4A7=U`/UI:*6C`;Y8]!^5.`P.***+"L%(5![`T
MM%,;5Q-@]!^5&P>@I:*`$V`=A1M`["EHH`:8PPY`/U&:41JIR`,^N*6BBP:+
M0****`"BBB@`HHHH`****`"D==P-+10!\D?M@?L'3:\;OQ)X%M_])D+37FC+
MA5F/4O!GA6/4IG#=1@DAO@/QS:S6-U/;W$,MO<0.T<L,L;1R1,."K*>5([@\
MBOVSKQ;]J']A[P=^TS9/<7L3:1X@5=L.JV:`2GT65?NR+['!]&%`'XP>+.&-
M<<O^L/UKZ>_:R_8`^(G[.YN;NZTN36]`A)(U73D:2%5]9%QNB_X%QZ$U\PH<
MR-]:`-&Q^Y6I9]*R['[E:EGTH`T[/^M:L'W1]*RK/^M:L'W1]*`/KO\`X(]_
M\G,:C_V`)_\`T=!7Z8U^9W_!'O\`Y.8U'_L`3_\`HZ"OTQH`****`"BBB@`H
MHHH`*;)((U))`P,]:Y3XK?'#PM\$-&;4?%>O:5H-ET22\N%C,S8SM1?O.WLH
M)/I7P7^V+_P6BNIK&YTCX5:9)9EU,9\0:K#AU[9@MFYSZ/+C'_/,UVX/+Z^)
MDHTH_/H9U*L8?$>R?\%5/^"DFD_L8_"NZTC1[N"]^(VMVKKIMHAW_P!FHP*_
M:YL?=4<[%/+L..`Q'JO_``3X^%EY\'?V.OA[HFI^<=731HKS4VE'[Q[RXS<7
M!8]V\V1\GO7XW_L>_`O5OVW/VX=`L-9N+S65N+W^V_$5[=.99);:!U=]['KO
M8I$!V\P8&!7[[0J%B0*`%"@`#H*]+.,)3P5.&$@[R?O2?X+]3GP\W4FZC]%^
MHZBBBO`.PJZOJL.BV$]W<S1P6MK$TLLCG"QJH)+$]@`#7SS_`,/=/V:/^BX?
M#OG_`*C$5>Q_'7_DC7BW_L#7?_HF2OR=_P"#;/\`8G^$G[17[$?B#6_'7P[\
M(^+-6M_%=Q:17>JZ;'<S)$MO;L$#,#A068X]Z]7`X+#U,+4Q.(O:+2LK=;]_
M0\[$XBJJ\*%*UVF];]+=O4_2[X4?M_\`P3^-NKQ:?X6^+7P\US4)SMBL[;7K
M9KF4_P"S%O#G\!7L`D5NC`Y]Z_./_@JI_P`$?OV;-)_8[\?>-;+PGH?PVU[P
MGH\^IZ=K&CG["%N8T+11/&#Y;B1PL>-N[YQM(.*ZW_@WB^/?B_X__P#!.?0;
M[QG>76IWNB:I=Z19WUTQ::\M82OEEFSEBF]H\GDB,9Y%.M@:+PCQ>'D^5.S3
M2ZJZM9ZCIXJI&O\`5ZR5VKIKUMJGJ?>%%&:*\D]!GGWQ1_:>\"?!+QAX=T'Q
M;XMT3P_J_BZ8V^BV=]<K%-JD@9$*0J>7;=)&,#NZ^M>@1MN0$]Z_)_\`X+W?
M\I%?V(O^QJE_]+]+K]7X_N"N_$X-4J%*LG\:;]+.QQX?$NI6J4VOA:7X)_J5
M];U>W\/Z-=W]W-';6EC"]Q-+(<)$B*69B>P`!)^E<K\"OV@_!G[2G@V3Q#X$
M\3Z-XMT2.Y:T:^TRX6>%9E"LT98<;@&4D?[0H_:/X_9X\>_]B[J'_I-)7P3_
M`,&K'_*-+5/^QVU#_P!)K.E2PBEA9XB^L6E;UO\`Y!4Q+CB8T+;IO[K?YGZ5
M4445PG8%9GC'QEI7P_\`#&H:SK>HV>DZ5I=N]W>7=U*L4-M$BEFD=F(`4`$D
MGH*T9I/*B9O[HS7Y@?\`!>+]H?7_`(]^.O`?[(?PTN"WBSXHW4,OB*6(%AIV
MGAR563'16V/(_P#TSB]'KLP&$>)KJE>RZOLENSFQ>)5"DYO5[)=V]D?H3\"_
MVCO`W[2?A>?6_`GBS0?%ND6\YM9+O3+M)XXY0`6C8J>&`*G![$>M=QUK\;/V
M?]";_@A%_P`%4+'X<RZC>'X&_'2T@32[V]DREEJ$86,,[G"AED<JW^Q<1$_=
MK]DHSE!]*TS+!1P\XNG+FA)7B^_?YID8/$NK%J:M*+LU_71]!:***\\[#,\7
M^*K+P1X=OM6U.[@L--TRW>ZN[F8[8[>)%+.['H%"@DGMBO`O^'NO[-&!_P`7
MP^'7/_49BKM_V[?^3,?BS_V)NK?^DDE?GC_P;S_L+_!W]H#_`()V6/B#QK\-
M?!GBC7&UZ_MS?:EID5Q.T:,FU2S`G`R<5ZV$P>&EA)XK$MVBTK*W5>9YV(KU
M57C0I6U3=W?I;MZGZ#?"C]O[X)_&W6(]/\+?%KX>:YJ$[;8K.UUZV:ZD/^S%
MO#G\%KV`2*>C`_C7YQ?\%6/^"/\`^S9I'['/C[QM9>$]#^&NO^$M(GU/3=8T
M<_80+F--T43Q@^6XDD"Q_=W?.-I!Q78_\&\WQX\8_'__`()R^']0\:75WJ=Y
MH^IW>DV5_=,6FO+6$CRV9B<N5+-'N/41C/-*O@:+PKQ>';Y4[--+JKJUGJ%+
M%U%7^KUDKM737K;KJ?=M%%*.M>4CT6>9?'S]KSX;_LO'3C\0O&_AWP<NK>9]
MB.JW2VXNC'C?LW'G;N7./45V7P^^(>B?%3P;IOB#P[JVGZWHNKPBXL[ZRF66
M"ZC/1T8$@@U^37_!SSX)M?B5\7?V8O#EZ\L5GK_B"ZTV=XR`Z1S3V4;%<]P&
M.*ZW_@@U\9]<_9=^./Q#_8Z^(=RRZUX#O;C4?"LDIP+VR<^:Z1YZJ5=;A0.T
MLG]VO?EDZEET<73?O:MKR3M=>AY"S)K&/#S7NZ)/S:O9^NMC]4B0!D\`5P_Q
MT_:/\#?LU>%8=<\>>*]"\)Z1<3BUBN]3NTMXY9B&8(I8\MA6./0$UVTW,3?0
MU^&'_!53Q=J7_!6#]LCQ[X3T"]G_`.%4_LR^%]4U;4KNV;]U=:DD+$KN'RDM
M-&(E_P!F&8CK7'E6`6*J\LW:*U;[=OFV=./Q?U>G>*O)Z)?UT2/VD^"_QP\*
M?M"^"(/$O@KQ#I7B?0+EWBBO].G$\$CHVUE##@D$8-=;7P%_P;0_\HIO"W_8
M9U3_`-*GK[]KGQ^&6'Q$Z"=U%M?<;82LZU"%5JW,D_O0444CL$4D]JXWL=!A
M?$KXD:)\)/!>H>(O$>K6&AZ'I4)GO+^]F6*WM8P0"SLQ``Y[UF?!'X[^$OVB
M?!47B/P5XET;Q5H<TCPK>Z;<+/"9$(#KN4D9!ZBOS:_X+4?%[6/VY_VIOAW^
MQMX"NI(SK-[%K'CF\MSD6-H@\Q(W(XPJ!I2#U;R!WKG?V'-3F_X(R_\`!577
M_P!GK5+BZ'PC^,)74O!-W=R%DM;MN(XBYX+'#6[=RZPGC=7O0R>^%]IS?O&N
M91[Q3M?UZ^AY4\Q<:W+;W$^5O^]V].GJ?KQ13()!*@;UI]>$>JPI&=4ZD#ZF
MEKYV_P""H_[<EE_P3W_9#UWXA3017NJHZ:=HEG(2%O+^8-Y:G!^ZJJ\C#NL;
M8P>:UH49UJD:5-7;T1G5J1IP=26RU/6OC#\??!/P`\+MK/C7Q;X<\)Z8N0+G
M5=0BM$<@9VJ78;F]AD^U?.%U_P`%W/V4[/5S9/\`&'0C*&V[TL[MXL_]=!$5
MQ[YQ7R__`,$Y?^"3$W[;>E:;^T'^U;J&J?$'Q/XQB74]'\.WMPZ:;I=F_P`T
M)>%<##*0RQ#"*K#*L<X_06V_83^#%IX>&DQ?"GX=KIP3RO(_X1RSVE?3/EY_
M6O4J4,!AY>RJ2E.2WY;)7\KW;M\CAIU<55CSP2BGM>[;];6L;GP*_:@^'G[2
MWA]M3\!^-?#/BVTCQYK:7J,5PT!/02*IW(?9@#7>U\6>$O\`@AK\(OA'^U_H
M7Q;^'M[XH^'5QI6Y[G0]`OOL^FZC(2"`ZL&98CSNB4A&XX7!S]I@8KS\7&@I
MKZO)M/NK-/MV9UT)U6K5DD_)A3+AS'"S#.1Z4^FSG$1KFM<W9\[ZG_P5B_9P
MT74KBSO/C5\/;>ZM)6@FB?5X@T;J=K*1V((-0?\`#W;]F?\`Z+A\.O\`P<15
M^='_``0`_9*^&?[2WC7]HN?Q_P"!?"_B^72O%RI9OJUA'=-;J\ER6"EAP"5'
M3TK])Q_P2H_9P_Z(E\-?_!%!_P#$U[^.P&7X6LZ$^=M6VY>U^IY.&Q&*Q%-5
M8**3OWZ.QZ!\`/VI?A_^U%I6HW_P_P#&&@>,++2IA;W<VE72W"6\A&X(Q!X)
M'->@UPGP._9F\`_LTZ=?V7@'PCH'A&SU.59[J#2K)+:.>11M#,%&"0.,UW=>
M)6=/G?LK\O2YZD.;E]^U_(*X'X]_M->!/V8M$LM3\?>+-"\(:=J$_P!FMKC5
M+I;>.>7:6V*6X)V@G'M7?5^4?_!V?_R:+\-/^QN/_I)+75EN$6)Q,*$G92.;
M'8ET*$JR5['ZKVLQG4D]/IBDU"[6QM'F=E1(U+,QZ*`,DT67^K/UJAXX_P"1
M0U/_`*]I/_0#7$E=V.E2O&YR_P`"?VE_`W[2VD7VH>`_%>A^+;'3+HV5W<:9
M<K/';S!0WEL5Z-M*G'O7>U^5G_!J9_R:]\5O^QYD_P#22"OU3KMS/!K"XJ>'
MB[J/7Y)G/@L0Z]"-5JUPKQOXT_M\_![]G+QF/#WCSXE>$?"FM-;I=BRU*_2W
MF,3DA7VMSM)5AGV->R5Y-\7?V%OA!\?O%YU_QO\`#GP?XKUKR$MA>ZGID=Q,
ML2%BJ;F!X!9L#WKFH*CS_O[\OE:_XFM;VG+^ZM?SO;\#B/\`A[K^S/\`]%P^
M'7_@YBH;_@KI^S3T'QP^'0/_`&&(C7YY_P#!R=^QC\*?V=/V4?`6J>!/A]X2
M\)ZA>^-H+*XN=+TR*VDG@:SNW,;,HR5W(IQZ@5^A/@W_`()8_LZ7?A#2I9O@
MM\.))9+2)G=M#A9F)09))'6O9J8/+84(5WS^]?3W>EO\SS:>(Q4J\Z/N^[;O
MU/9_@O\`&_PG^T-X$A\3>"O$&E^)]`N)9(8K_3YA-!(R-M<!AP2#P?>NLKE_
MA!\%O"OP"\%Q^'/!F@:5X:T*&5YH[#3K=;>WC=SER$7@$GD^YKJ*\2?)S/V>
MW2^YZL;V][<*X&U_:<\!7GQXG^&<?B_07\>VT'VJ70!<K]O2'8)-YCZ@;&5L
M^A%=]7Y.^#/^5K_Q/_V*`_\`35;5V8'"*O[2[MRQ<ONM_F<V*Q+I.%E?FDE]
MY^L5%%%<!UA5'7_$=CX9TB>_U"^L]/LK13)/<7,RQ10H.I9F(`'N33/%/B6U
M\'^'[S4[^9+>QT^WDN;B9SA8HT4LS'V`!/X5^-OP;T;QM_P<7_M.>)]=\5:Y
MK/AC]F?P%J/V6PT+3YC;MK4HPR*[=Y"FUY&(.P.JK@G=7?@,#[=2JU)<M.&[
M_))=6SCQ.+]DU"*O*6R_7R1]\?$#_@M?^S!\,]7DL=2^,OA.>YB;8W]G/)J,
M8/\`OVZ2*?P-=I^S[_P4L^!O[4>KQZ?X(^*/A'6=3DQLT_[6+>\E_P!V&7;(
MWX*<4_X2_P#!-;X#_!CPU#IOAWX4>!;2WB0)YD^CPW5Q(!W>68-(Q/<LQ->1
M_M@?\$)O@)^U5:Q7-EX?C^&_BFVF2:#7/"D4=A.N&R0T:CRGR.A*[@>0>QW4
M<L;Y;SCYNS_!?YLSE]=BN:T7Y:K\?^`?9ZR*_P!U@<>AI:Y[X5_#Z/X6?#_2
M/#\6IZQK$>CV<5FM[JMS]IO;H(N`\TI`WN>[8&370UY35FTCO3NKA03@45D>
M/_&VE_#?P1J^OZU>P:=I&B6<M]>W4QQ';PQH7=V/H%4G\*(IMV0_4XWXP_M<
M_#;X#>,=$\/^+_'?A?PUK7B,@:98ZA?)#/>DN$&Q2<D%B!GUKT=)%D^ZRMCT
M.:_!OPY^QWXM_P""\T_Q\_:"OY-1TZ.T0Z1\+[-I/+5GMG\T(W/(V`(Q''FW
M#M_!7Z)_\$-?V]9OVV?V1;>T\0S,OQ#^'A30/$<,_%Q(\8*Q7+@\YD53NX'[
MQ)*]K'Y1&A0]I3E>46E-?RMJ_P!W3U/*PF8NM4Y91M&7POO;?_/T/M.BBBO$
M/5$8X4FN`^(W[3O@/X2>/_#_`(3\2>+]!T3Q+XK81Z/IUY<K%<:D^X)B)#RQ
MW$#CN17?R?ZMOI7Y,_\`!:'_`)3(?L;?]A5/_3A#7?EF#6*KNE)VT;^Y7./'
M8ET*?M$KZI?>TOU/UF7.T9ZXI:**X#L"BB@]*`,KQ?XTTGP'H%SJVLZII^D:
M58(9+J\O+A((+=!U9W<A5`]20*^6O$G_``7-_97\+ZZ^GW/QC\.2SH^PO:0W
M-W!G/_/2*-D/U#8KXM_X.*_'5QXF_;)_9[^%WC'6]0\/_!KQ!<0WNNS1S&&&
M=S>"*7S&Z?NXMI&<[?.)K]&OA7^P'\!?"?PUT_2_#WPP^'CZ%+:H(F71K:Z%
MU&RC#&5U9I-P.=Q8YSG->U]2P]'#TZ^(YFYW:4;))+N[/4\SZU6JU9TZ%ERV
M3O>_?96T.P^`'[4_P[_:B\-'5?A]XU\-^+[*,[9FTR]CF>W/82(#OC.,<,`:
M]"KYP_9V_P""4?P4_95_:*UKXG>!?#,F@^(-:M_LQMX+N1;"S4_?\F`':N\X
M)SD#'RA>:^CP<UYF(5!3_P!G;<?/?\#NHNHX?O59^04445@:A1110`4444`%
M%%%`!1110`DB"5"K#(;@U\^?'_\`X)B_"7]H&2>[NM"_L#6)R6;4-'(MI&8_
MQ.F#&Y]25S[U]"44`?EW\7?^"'OC/PK++/X-\2:3XEM>66"\4V-R!Z9RR,??
M*_05\^^.OV,OBG\*6D_MKP-XA@BC/,\-JUS"?H\>Y?UK]QL9I"H/84`?@%%;
MO;2E)$DCD4X*LI#+]1VK2M^1C@\=J_=3Q)\._#_C)"NKZ'H^JJ1@B[LXY\_]
M]`UQ&L_L7?"C7)-T_P`._".?^F6FQP_^@`4`?#?_``1_?R_VE]2]M`GZ\?\`
M+:"OTN>["XX))K\@?^#C+0T_8A^'?POUGX0W.I_#C5-;U>\L[Z[\/7\]C+=0
MB%&$;%'!*[@#CID"OSA\$?MG_&#7G_TWXK_$RY$@`8/XGO2&^H\VOJ,MX6J8
MS#+$J:2=]->AX]?.(4L0\.XNZ_RN?U-_;5`YX^IJI?\`BJPTNW:6YNK>WC3E
MGEE1%4>N2:_G`\*_%3Q5XDVG4_$_B/4=W!^U:G/-GIUW.?05ZQ\/M%L]4NDD
MN;.VN'SG=+$KM^9%:SX4=/XJGX?\$ZH8Q2U2/VSU_P#:X^&7AF0I>>//"<<H
M./+75(7D_P"^58G/MBLA?VU?!NJ$+HD/B7Q&Y^Z-/T:XV-]))%2/'ONQ7Y^?
M!ZVCM3$L4:1JN``BA0/RKZG^#G+P_2O*Q6`I8?75_,Z8S;5SO/&/[67B6"W9
M])\`M;X!PVNZM%;L#Z[+<3Y^A9<^U>!?%?\`:9^)VOP212^*H-$@;/[K0;%;
M9@/0RRM*YQZH4_"O6_BF!ODX'>OG?XD?ZR7ZFM<OITVU[J^Z_P"9-0^?OB7;
M&]UF?4;N6YO]1G!$EY>7#W-PX]#(Y+$>V<5XEX]E6%9&;(49).*]P^)$@C20
ML54`$DDX`XKWG_@F=_P3Y?XF>)-/^*?C33V30=/F6?P_IURN#J,JD%;R13_R
MR4\QJ?O$;L8"Y^K>,IX6C[6>RV]>QQRIN<M#VO\`X)%?L1R_LR?!>?Q!K]H;
M?QKXU$5S>Q2+\^G6R@F"U]F&YG<?WGQSM!KZ_48`%(D:H3A0/H*=7Y]B<3/$
M576GNST*<%"*B@HHHK%%G)?'7_DC?BW_`+`UU_Z)DK\2O^"$?[`_Q)_:B_9+
MUK7_``A^T=X_^$6G6OB2>S?2-#@\RWGD$$#&<GSD^8A@.G117[=?&6QGU7X5
M^);2VB>>YNM*N(HHT&6D=HG"J/<D@5\.?\&W7[/?CC]FK]B?Q#H7C[PKK7A+
M6+CQ5<7D5GJ=N8)9(6M[=0X![$JPS[5[N6XMT,NK.#7-S1WL^]]&>1B\/[3%
MTFUI:7==NUC/U/\`X-[8OC-JMG)\:/VA_C'\6-/LY1*NG7M]]GMF([8+2%0?
M]D@X)P17WI\&?@]X<^`'POT;P=X2TFTT/P[H$'V:RLK9=L<*9+'W)+$L2<DD
MDDDDUTR\@4M>;B<?B*\5"K*Z6RV2^2T.ZAA*5%MP6KZ]?O"BBC/-<9TVN?D#
M_P`''O@V;XB_MF?L@Z!;ZM?Z#/K>M7EC'J5BVRYL&DN],031'LZ$[@?4"O=T
M_P""'?C!E!_X:_\`VC!_W&#_`/%5S7_!9W]G/Q[\:OVZ_P!DO7/"7A'7?$.C
M^#/$4EWKEY96K2PZ9$;S3G#RL.%&V*0_1#7Z4V[!H5([BOH\1F-2C@L/&A);
M2OHG]I^3MH>)1P,*F)K3JK[2MJU]E=F?FS\8_P#@BMXM\,?"'Q5J<G[6G[0F
MH)IVCW=RUK<:ONBN0D+L8W&[E6Q@CT-)_P`&K9!_X)J:J>@;QOJ''I_HUG7W
M]\>M*N==^!GC2QLX)+F[O-"OH((4&6E=K=U50.Y)('XU\8?\&XOP!\:_LW?L
M":CX>\>^&-9\):X_BZ]O%LM3MS!,T+06JK(%/\)*,`?]DU#Q]2OEU2-:2OS1
MMLN_:P+"PHX^FZ:=N67=]NY]]T445\^>V>=?M3_M'^'_`-E+X!^+/'OB:7R=
M(\+Z?)=R`,`]PX7]W"GJ[N51?=A]:_%K_@D;_P`%!?@KX9_:4^*'[1'Q^\?6
MNG_$[QE?/:Z38-I]U<_V79D`LR-'&R@$".%1G(2$_P!ZOJK_`(+9_!OXQ_M_
M?M(_#;X#^$O"GB:Q^%KZA;ZAXJ\4FV9=.9B2=N_HPAB#,!T:1U'5:^\OA]^Q
MY\,/A]X*TS0K'P#X0%EI%M%9P>;I%O(^R-`B[F*$L<#DDY)YKZ+#U,/A,%:I
M=SJ[V:344]$WKN^G8\6M&M7Q-X62I]T[-OKTV1^8_P#P68_X*%_LG?\`!0?]
MCS4-"T?XFVA\<>&Y?[7\-2G2KU";E1AH-YB`594RO)`#;">E?5O_``0I_P""
M@8_;M_8[T[^V+M9_'?@=$T;7PS?O+DJ,0W1]?-C`)/\`?5Z^HV_9K^'3=?`/
M@K_P1VW_`,17YH^)/V4/B/\`\$W?^"REO\1_A%X&\0>(/@_\5E,?BK3]"LC)
M%I!ED'G-L3A0DNV=,`?*TB#`JJ57"XK"RP<+Q<?>CS-/7K&]EOOZDRA7H8E8
MF;33]V5D_D^NWY'ZR45':OYD"L2<L._6I*^:N>XSR;]NW_DS+XL_]B;JW_I)
M)7Y'_P#!%W_@GY\5/VB_V%;?Q+X-_:9^(GPMTY]7OK>+0M(@+6:2H5S)D3*<
MN2,X7BOU[_;,T"]\6_LI_$K2=+M9[_4]4\+:E:6EK"I:2XEDMG5$4=R20!]:
M^9?^#>[X'>+_`-GO_@GG8^&O'7AG5O"^O1Z]?W+6.I6YAF6-V78^T]C@U]!@
ML7*AEM7D:YN=;V>EGT9Y.)P_M,=#F3MRO9VUT/SP_96_9O?]J/\`;Q\0_`7]
ML?XE_%75/&'AZZ\W0-,N?$#G2?$"J"WREPS`O'^\385+*6&59<']T_A!\+?#
M_P`$_AIH_A3PKI-IH7A[0K<6MC8VR[8X$!/`]22223R223R:^,_^"U7_``3(
MO/VP?AK9?$'X>YTKXS?#@B_T&\M#Y5QJ*1OYGV7>.0X(WQ'L_'`<FO8O^"9W
M[0?Q&^._[.6F2?%GP+XC\"^/]%VV.K0:E9M;1ZBP'RW<.>"KC[RC[K;ATP3>
M:XAXO#PQ-.5DM'#16?=+JG^!.`H_5ZLJ4HW;U4M[KLWW1]'4HZT@H)P*^>/8
M:Z'Y-?\`!QE_R=%^R'_V.3_^E=A71_\`!?;]GS7?A%XD\`_M:_#N`Q^,/A+>
MP)K0C!_TW3B^%9\<E5+M&W_3.9NRUJ?\%UOV;?'_`,>OVB/V8]1\&>$->\36
M/A3Q0UYJ\]A:M*FGPFYLF#R$?=&$<_\``37Z'?$#P+I'Q0^'VK^'=<L8;[1]
M=LI-/O;>505GAE0HZ'V*L17TD<P5"AA*BU24U)>3>J^:/"^J2K5<1%Z7Y;/S
M2T9\1?M\_P#!730?AM_P2ST[XL^"+Q&UWXHZ>+'PK"KAIK>]E0I*Q`YW6V'R
M/[\:CO7%?LM?L&O^P_\`\$1OBG'K<!'CSQQX/U37O$DTHS,DLEG(8[=B>3Y2
M'!S_`!O(>]?._P"PK_P10^(GAO\`X*00>'OB%#K-_P#`OX,:M<:]X7DO07L-
M5EF='@2)3D$[EC>5<8S"0?O5^KO[=/A/4/&?[&GQ1T31;&XU+5=5\*ZE9VEI
M;1EY;B:2VD5$4#J22!5XNIA\(X87"RNI24I/RO[J^2U?F&'C5KJ5>O&S2:2\
M[:OYO;R/E_\`X-H?^44WA;_L,ZI_Z5/7W[7Q/_P0#^"_BW]GW_@G#X>\,>-O
M#NK>%_$%KJNH2RV&H0&&>-'N&9&*GL1R*^V!R*\G.9*6.JRB[KF?YGH9:FL)
M24E9\J_(*\B_;D_:WT/]B#]F;Q3\1]?\N2WT&T+6MLS[6OKI_EA@'N[D#/89
M/:O6KEBENY'4#UK\L/\`@JY\`?BW_P`%,?V\_AO\'X/"?BK1O@;X6NDOO$'B
M*2V>*RU"8C?)L<\,4A'E1G_GI*_;FHRNA3K8A*J[05W+T71>;V*QU6I"B_9*
M\GHO5GSO_P`$5OV^/@1\"?$'Q'^,OQO^)%K'\8OB5J,@FC?3;N8Z?:;][!62
M-E'F28.T$X2*,>HKL/\`@MO^WI^S!^W5^S/:W7@OXFVW_"S_``%?+J_AN1-,
MO(9)VW*);?S&B`7<H5P20-\*=!FOUH\/_LJ_#7P_I5O96_P^\%1VUI$L,*_V
M+;':BC:!RGH!5F[_`&:_AX\)"^`_!BD]"-$M@?\`T"O5><8;ZTL6H2YEM[RM
M9*UK<NUM+'G1RW$>P^KN4;/R=[[WO?>YX7_P1X_;WMO^"@7[&WA[Q)=3Q'Q=
MHB#2/$D(/S+>1*`9<=EE3;(.P+$?PU]6U^3_`,(?V5?B9_P2^_X+'ZS>_#[P
M1XCU_P"`?Q<"-J)TFS::VT"65B07"\*()]Q&!Q!*1VK]7+1B\()).?6O/S;#
MTH5O:8?X))->5]T^UF=^7U*LJ7+67O1T?GY_,DK\N?\`@ZY\%ZIKG[#?@C6;
M2*6XTSP[XRAEU%$!(C62UN(TD;T`?"9]91ZU^HU<;\??@CX>_:0^$VM^!_%F
MG1:KX=\16K6E];2<;D/(93U5U8!E8<@J#6&78Q87%4Z[V3_X?\"L=0]O0E1O
MN9G[)OQ.T3XO?LV>`?$/AR:*XT75_#]E<6CQD;54PJ-F.Q4@J1V*D=J]%!S7
MY.?"_P#9R_:N_P""+FOW^E_##1T_:#^!EQ<R7-MH0NOL^L:+N)9MBD'!SU$8
M=7.6*(2:]6L_^"\>H06?D:A^RO\`M,P:TOR-;0^&?-M]_/'G%E.,XYV5UU\I
MJ3FYX5J<'LTU?YIM-,YZ681C'EQ"<9+R?X-71^AM%?FOX,^*G[:_[>OQZ\,Z
MKI/A]OV:/A7H-V+J[_MG9>:KKB=T>W9<D%3@*5C52=VYB`*_2*SCDC4B1MYP
M!GU]ZX<7A70:C*2;>Z3O;UMI^)V4,0JMVHM+S5K^A-39_P#5&G5'=.(X&8YP
M/2N5&S/P5_X(Y_L(ZW^V/\0/CW<Z3\9?B3\*TT/Q68I8O"U[]G34#)+<$-+R
M,E=I`^IK[H'_``0Y\8?]'@?M&?\`@X/_`,57RA_P37\6_M!?\$U?&_QB1OV6
M_BEXWMO'/B-M0MKBSA-LB1QO,%/*-N#"0$8QTKZO'_!73X^_]&1_&/\`\"!_
M\9K[;-*N.EB92PTH\CM;6'9=]=SY?!0PD:*C74E*[_G[OMH?6/['O[-^H?LL
M?!^'PIJ7CWQ9\1[B&ZFN?[9\13^??.)&R(RV?NKV^M>JC@5\Z_L(_M>^/?VI
MKCQ(OC?X)>,O@_\`V,L!M/[>E\S^T_,,F_R_D7[FQ<_[XKZ*KX_$JHJK]K\7
M6S3_`"T/H\/*G*FG3VZ;_KJ%?E)_P=G1NW[(7PV<(QCC\7'<W9<VDV/Y'\J_
M5NOG7_@J#^P;9?\`!1/]E#6OA_-=0Z;J;.FH:-?R@LEE>Q;MC.!R496=&QSM
M<XR0*Z\HQ$*&,IU:FB3U,,RHRJX6=..[1[YX?U&+5M,BN8'62"X198W!R'5A
MD$>V*J_$&Y2T\$ZK)(P1$M)69CT4!&)-?F%^S/\`\%$/VB?^"?\`X#TWX:_'
M7]GKXE^,X_#,":?8>*/!MM_:OV^WC&V,NH^5F"@#=O4D`;E!R2?M,?\`!1+]
MHG]O_P``:E\-/@7^SS\2_!2>*(WT^_\`%/C2W&E"PMG!678K?(K%21N\QB`3
MM4G!'3_8M95+WCR7^+F5K=_^!N81S*DJ25GS6VL[W'?\&I6X_LK_`!4D"DQ2
M^.I0C_PL19VYX_`C\Z_5.OG'_@ES^P;9?\$[OV3=#\`6]U!J6J>;)J6MZA&I
M5;V]E`WLH/.Q0J(N>2L:DX)Q7T=7/G&*AB,;4K4]F]#?+J$J.&A3GND%%%%>
M:=I^6/\`P=<?\F8_#G_LH%M_Z07M?ISX%_Y$G1_^O*'_`-%K7Y\_\'(_[.WC
MK]I?]EGP)HW@#PGKGB[5+#QK#?7%MIEL9I(8%L[M#(P'10SH,^K5^@_@F-H?
M!VE(Z/&\=I$C*PPRD(`01ZYKU\3*/]G4(WUO/_VT\S#Q?UVK*VEH_J:E%%%>
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M019(3#M\VQF3:V2CC[M>SEU2G4PM3`U)*+DU)-[771]DSR\92J1KPQ,(N2BF
MFEO9_P"1^FE%?G3X?_X+<?$+P'$NG?%+]DSX[Z/KL(VSGPWI8U>UD8=61LQC
M:?JWU-<]\4O^"B/[5/[:^C2^%/@%\`O&GPT&K+Y$_B_QQMTXZ:C<%XHF!PP'
M.X&0CLA.#6<<FQ*?OV2[N2MZ[FKS*CM&[?9)W_(_3>BN`_9@\$>-OAS\$-`T
M;XB>+8O''C&QME34M9BM%M4NY/9%P,`8&[`+8R0"<5W]>9./+)I.YW1;:3:L
M-FD\J(L>U?D;_P`',G[?5OH'ASP_^SUHFM6VE7WC-X;SQ7?L69--T[S,11/L
M!;$CJTC*!G9$."'K]4OBUXOF^'_PSUS6[?2=3UZYTJRDNH=-TZ(RW=^Z*2L,
M2CJ[$`#W-?FC_P`$??V`?&GQ._:)^)_[1'[1O@R6T\8>*]0>RTC0]>L@WV&W
M.TO((I`0%"^7#'W"QOZU[&3>QHREC:^JI[+K*73[M[GF9DZE11PU+1RW?9=?
MOVW.Z_92_P""O_[%_P"R5^SYX7^'GASXG0)I/AFQ2TC<Z-?*]PP&9)G_`'/+
MNY9B?5C7PW>_\%$_A'^R/_P65B^+?PB\6PZ[\+_BJOE>-K&&TGMUL)9I!YLV
MV1%!Q+LN`0#_`,M5XSS^XH_9K^'(''@'P5_X([;_`.(KQ3_@H1_P32\!?M;_
M`+)OBSP5IGA?PQH&NWML;C2-1M-+A@DM;V/YHCN10=I/R,.ZNU=6!S#!1KRY
MXRM4TE>2:UZ_#TW.;%83%NG&SC>%FK)WTZ;]=CZ5T75H-9TJTNK66.XM;J%9
MHIHVW)(C`%6![@@Y!JW7PU_P0B\4_%W1_P!E5?AS\9/!?BGPUKGP\<:?I=]J
MMLR1ZKI_/E!)#PQBP8^/X!'UYK[E%>'BZ'L*\J-[VZK9GKX>M[6FJEK7Z=A)
M/]6WTK\F?^"T/_*9#]C;_L*I_P"G"&OUEEXB;Z&ORN_X+>_!GXIZU^WU^SS\
M2O`'PQ\5_$;3OAVSWVH0Z/;%SN2ZCE$1<`A&8*<$BO2X><5C'S.UXRWTWBUU
M.+.(N6'=NCC_`.E(_5.BOSY'_!77X^`?\F1_&/\`\"!_\9KUO]BW]N_XG?M+
M?%FXT'QC^SK\0/A/ID%D]TNK:U-OMY9%*@0@>6OS$,2.?X37+5RO$4X.<K67
M]Z+_``3-Z>/HU)<L6[^C7YH^JZ**#TKSSL/'/VQOV%?AO^WC\-%\,?$?0(=7
MLX',MG<QL8;S3Y2,&2&5?F0D=1R#W!'%?#TG_!"OXQ?LI64DW[.7[4'C#PU:
MP,7MO#WB",W&GL>H#,A,>,\?\>Y->Z_\%)/B/^UI\$_'/ACQ3\$_#?AOQWX"
MTS+Z[X=48UF]."#AG.#&`05\KYPP&59<BO.(/^"[FO2:*+:?]E']H]?$ZX06
M2>'B]F9?0W!(.,]_*Z5]!@%CH45]7E&47JXMQ=O52V/'Q3PDJC=6+4EL[-7]
M&MSGOV`_^"JWQ=\/_MQK^S/^TMX=TFR\=7*,=)U_2P(X=1(C:10Z+\C+(BL5
MD3;\PVL@.2/TV08S]:_+[]C#]B/XR_M=?\%(K7]JKX\>'+;X=V_AZV%GX6\)
MB82WB*L<B1M,?X0OFR.<X9G;[JJ,']0@,5S9RJ*JQ]DDGRKFY?AYNMOP-\ME
M5<)>TO:^C>[72X4445Y!Z(4444`%%%%`!1110`4444`%%%%`!1110`4444`?
MD5_P=K_\D4^#?_8P7G_I.M?D1\,_]8GX5^N__!VO_P`D4^#?_8P7G_I.M?D1
M\,_];']!7Z[PO_R*J?K+\V?#YA_R,Y?+\CW_`.'_`-U/J*^@/A?UCKY_^'_W
M(_J*]_\`A?UCIXO8]S#_``GTG\)O]9'^%?4GP;^_%]*^6OA-Q(GX5]._##5K
M30M.-[>W-O:6=L@>6::58XXU]2QP`/K7PV;:Z'J4MK'0_%,9DD_&OG#XLZE#
MIBN\K[2[^6B`%GE<G"HJC+,Q/`5023P!7O\`J47B'XX7QA\&Z.]S8R9#:YJ"
MO;:8H_OQ9`DN?;RAL/\`SU%>F?!']CCP[\*]4AUO4))?$OBH*3_:=Y$H%J6Z
MK;1`;(%ZC(RY'#.U<.'Q,*$;SW[=?^`4TWHCYX_94_X)TW'CC6K/Q;\2]-:W
MTJ-Q-8^&YQ\]P0<K+>`'`7H1!G_KIW0?<MK:QV4"QQ($C4851T`]!3HXQ$@4
M9P/6G5P8G%5*\N:;VV78NG34-@HHHKG+"BBB@!KQ*YR1S0D*QDX&,TZBE9`%
M%%%,`HQS110!$;.,L25R3SU-2*H48'`%+12L@$90RD'D&DCA6$848S[TZBF%
M^@4444`,:!&?<1S]:>!@444`%1&SB+9V#-2T4K(!$C$8P!@"EZT44P&/;I(<
MD9/UHCMTB/`Z^]/HH87&O$LB;6&1Z4U+6.,\+C!SU-244N5`%!&X<T44P(S:
M1L02N2.A[TI@4QA,?*!C%/HI60$8M8PP.WD'(.3Q2O`DF=PSGJ*?10DEL`R.
MW2+.T8R,4_I110DEL'F!&1@U&;2,D';TQW]*DHI@`&****5EL`QK9&?<5&0<
MY]Z<B"-<`8%+119`%&***8$9M(R^XKDYSR:!:QA<;1@5)12:0/48MLBG@?J:
M?113L`4DB"1"IY!Z\TM%`$?V6/\`NY_&C[)'_<%244K(!L<*Q?=&*=113`*"
M-P(/0T44`1"SC`X!';@FE^QQD@[>G3FI**5D*RO<14"+@<`4M%%,84444`1M
M:QN22N<^_OFGJH1<#@"EHHL.X4444""F"!!+OQ\WKFGT4K`%%%%,`ILD2RKA
MAD4ZB@35]R,VD9&-O'IDT?94';]34E%*R&&,4444P$=!(I5AD&F+:HA!"X(]
MZDHH`*;)"LJX8<#WQ3J*35]P(X[2.%LJI!^IJ0#`HHI@!&X$'H:8;9&/*YI]
M%*R`C^RQ_P!T4J0)&<@8I]%%EN`4444P&R1+*,,,TW[)'G[N?J:DHH$U?<C%
MM&&#!>0<U)110,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#\BO
M^#M;_DBOP:_[&"\_])UK\B/AF/WD?X5^NW_!VP<?!3X-^O\`;]Z?_)=:\M_X
M)(?\$&K_`./_`('TOXA_%:ZO=!\*ZBBW.F:';?N[[5(3G;++)_RQB8=`H+L#
MG*\9_4,FS"AA,FA4K.RN_7=GQV*P\ZV9S5-7:M^1\N?#*)]2O;:TMHY+BZG.
M(H(D,DLA]%4`D_@*^RO@/^Q7\7?&D<,EC\//$,$,F")M3B738_KB<J^/HIK]
M8O@;^S!X#_9NTG[!X)\*:)X=MVCV2-:VX$T_3F20_.YXZL37?;!GH.*^<QG%
M,IW5&&GG_P``^CHX-Q7O'PW\'?\`@FUXY8POK_B/1?#D*X#PZ=`^H7!'M+((
MT1O^V<@S7T;X!_8R\%^![FWN[BWN_$NI6I#17FMS?:VB8=&CCXBC.>\:+7JZ
MH%/"J/I2U\[6Q]>K\3MZ:'7&'*,BA$/`Q@#``&,4^BBN0L****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`^'O^"LG[*%M^V5^T?^S'X0U&`7
M.A0>)[_5]7C(^62TMK5971O9V"(?^NE?;=C8Q:=;)#!&L,4:A$11A5`&``/I
M5/4/".G:IXDT_5Y[9)-2TN*6&UG/WH4EV>8!_O>6F?\`=K2'(KIK8F52E3I-
MZ0O^+;,:=",9RJ):O]-`HHHKF-@HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
$B@#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
